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ABSTRACT
Background:
Medulloblastoma is the second most common paediatric central nervous system tumour.
The treatment is also associated with significant morbidity on a long term basis. We looked
at the clinical profile and outcome of children treated for paediatric medulloblastoma under
the paediatric haemato-oncology unit and also looked at their molecular subgroups, to see if
molecular subgrouping can be used as a better prognostic marker.Quality  of life of survivors
was analysed using Peds QL.
Methods:
109 paediatric medulloblastoma patients were operated on in the neurosurgery department
of this hospital between the years 2004-2014. Of these, 73 patients presented to haemato-
oncology for chemotherapy. In addition to this, 3 more patients with biopsy proven
medulloblastoma, operated elsewhere, came here for further management. We looked at
their clinical profile and outcome in detail. Tumour immunohistochemical markers and
histology were used to classify the tumours into WNT, SHH and non WNT/non SHH
subgroups. The clinical profile and outcome were compared with the different molecular
subgroups. In addition, quality of life of survivors was also analysed using PedsQL, a
validated tool for studying quality of life of brain tumour survivors.
Results:
Of the 76 children, 50 completed treatment. Tumour markers were studied in 43 of the 76
tumours, to classify the tumours into molecular subgroups. 26 out of the 43 tumours in our
study belonged to the WNT subgroup. Statistical analysis showed that WNT tumours did
better than non WNT tumours in terms of survival. However, there was no difference in
their quality of life, probably because of standard treatment received by all patients.
Conclusion:
On comparison of clinical profile and outcome with molecular subgroups, WNT subgroup
has been shown to have a better outcome compared to the other groups. However quality
of life analysis does not show any added advantage. Stepping down of therapy for the
tumours with better prognosis might be useful in decreasing the long-term morbidity of
survivors.
Keywords: Medulloblastoma, molecular subgroups, immunohistochemical markers, disease
remission, recurrence, death, long term sequelae, quality of life.
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INTRODUCTION 
Medulloblastoma is a small blue round cell tumour which arises, most often, from the 
posterior cranial fossa.  It is the second-most common primary malignant central nervous 
system tumour world-over in children, forming 35% of all CNS tumours in children, as 
reported by Packer et al.(1) The incidence varies from population to population; a 
multicentre study done by Sarkar et al in 2010 has shown that among the paediatric 
population in India, medulloblastoma accounts for 22.4 % of all CNS tumour, second only to 
astrocytoma.(2) 
The disease has a bimodal distribution, with the maximum numbers presenting between the 
age groups of 3-4 years, followed by 8-9 years(1). There is a male predominance for 
medulloblastoma. The most common site for medulloblastoma is the posterior cranial fossa, 
especially near the 4th ventricle. This classic location of medulloblastoma results in 
obstruction to the CSF flow leading to hydrocephalus. Children present with features of 
raised intracranial tension and truncal ataxia, due to obstruction to cerebrospinal fluid flow 
and the relation to cerebellum respectively(3).  Medulloblastoma responds very well to 
radiotherapy and chemotherapy, second only to germ cell tumours of the CNS in this 
response to therapy.(4) 
Further studies in this field have shown that medulloblastoma with certain characteristics 
do better than the rest. This has led to various classifications, as well as risk stratification 
methods based on the same. 
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Various classification methods have been used for medulloblastoma over the years.  The 
initial classification for medulloblastoma was based on the location of the tumour, i.e, 
whether vermian or cerebellar. The WHO 2007 classification is based on histology, whereas 
the Boston consensus conference held in 2010 classified medulloblastoma into 4 subgroups 
namely sonic hedgehog (SHH), wingless (WNT), group 3 and group 4 based on 
immunohistochemical markers. (5)(6) This classification is however not yet widely used In 
India. The four variants have distinct demographics, clinical presentation, genetic 
abnormalities and outcome, hence the use of the molecular subgrouping helps in better 
prognostication. 
In this study, we looked at the clinical profile of all children with medulloblastoma who were 
treated under the paediatric haematology-oncology unit of a tertiary care hospital in South 
India between the years 2004-2014. The clinical presentation, course of illness, treatment 
details, outcome and late complications of the children were studied in detail. The quality of 
life of survivors was assessed in addition to this. Molecular subgrouping of these tumours 
was done with the help of immunohistochemical markers as well as histology, and 
correlation between the clinical disease course and markers was analysed. We hope that 
this will help us in better risk stratification of the disease in the future. 
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AIMS AND OBJECTIVES  
1.  To study the clinical profile and outcome of children with medulloblastoma who 
presented to the paediatric haematology-oncology unit for treatment between the 
years 2004-2014. 
2.  To look at complications of treatment: both during therapy and late effects. 
3.  To determine whether the histological and molecular sub typing correlates with 
clinical presentation and outcome. 
4.  To assess the quality of life of survivors 
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REVIEW OF LITERATURE 
Introduction: 
Childhood malignancies form an important cause of mortality in childhood as the deaths 
from infectious causes have decreased as a result of better hygiene, health care access and 
facilities. According to population based studies done by the International Agency for 
Research on Cancer, malignancies are the 9th most common cause for deaths in the age 
group 5-14 years. The incidence of childhood malignancies in India ranges from 38-124 per 
1,000,000 population according to the 2006 National Cancer Registry Program 
reports.(2)According to the NCRP reports, the age adjusted rates of incidence for childhood 
cancer incidence among boys is 18.6-159.6 per million for boys, and 11.3-112.4 per million 
for girls, between the years 2009-2011. Of these, CNS tumours account for 6.6-19.8 per 
million among boys and 3.0-16.0 per million among girls for the same time period.(7)Central 
nervous system tumours form the second most common malignancies in children after 
haematological malignancies world-over.  Incidence of CNS tumours in India varies from 22-
25 per million population according to Arora et al. (8)Medulloblastoma is an important 
tumour among these. 
Medulloblastoma was first described by Bailey and Cushing in their article in the 1925 
edition of Archives of Neurology and Psychiatry, where they labelled it a “common type of 
mid-cerebellar glioma of childhood”. Almost a century later, medulloblastoma is still an area 
of intense clinical research and new advances as it still forms a big chunk of paediatric CNS 
tumours.(4) 
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Medulloblastoma has a predilection for posterior cranial fossa involvement, causing 
obstructive hydrocephalus due to ventricular obstruction, and ataxia as a result of cerebellar 
involvement. The most common presenting complaints are therefore related to the same: 
the obstructive hydrocephalus causes raised intracranial tension, resulting in headache, 
vomiting and cranial nerve palsies, and the cerebellar involvement caused unsteadiness and 
giddiness.(4) The symptoms may be more non-specific in the younger age group. The 
common presentation in infants are usually a rapidly increasing head size, and “sun setting 
sign”, or upward gaze palsy, as a result of dilatation of the ventricles.(1)Vomiting is also a 
common sign in young infants. Brasme et al studied the mean duration between onset of 
symptoms and diagnosis of medulloblastoma, and found that the median time interval 
taken for diagnosis is still 2-3 months. (9)This was in spite of vast advances made in 
radiological diagnostic techniques, and was attributed to the inconsistency of symptoms in 
children, and to lack of focal neurological signs and symptoms till late in the disease course.  
Gerber et al studied whether a longer duration of symptomatic period was associated with 
worse prognosis in the disease course of medulloblastoma. They found that there was no 
adverse association between a longer time taken for diagnosis and the clinical prognosis. 
This study also noticed that patients with non-metastatic, non-aggressive forms of 
medulloblastoma had a longer time interval between the time of onset of symptoms and 
the time of diagnosis. (10) 
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Classification: 
Various classification methods have been used for medulloblastoma over the years. The 
important ones among these are the following: 
(1) Classification based on the site of origin of the tumour: 
Medulloblastoma were initially classified based on their location, into those arising from the 
cerebellar vermis, or from the lateral cerebellar hemispheres. The cell of origin has been 
found to be different for medulloblastoma arising from these two sites. Those arising in the 
cerebellar hemispheres arise from the external granular cell layers of ventricular 
subependymal matrix whereas the vermian tumours are thought to arise from the Purkinje 
neurons.Giangaspero and Radner  in their 2000 publication have confirmed the same. (11)  
Polkinghorn and Tarbell, in their publication on the various classification methods used in 
medulloblastoma have shown that tumours which arise from the external granular layer in 
the cerebellar hemispheres are dependent on the SHH pathway for proliferation, when 
compared with those arising from the midline, and are more likely to be showing mutations 
consistent with SHH pathway.(12) Studies by Gibson et al have also confirmed the same, 
with GNPCs of the cerebellum being shown as the site of origin of SHH.(13) 
(2)Classification based on histology of the tumour: 
The WHO 2007 guidelines for classification of medulloblastoma are based on the histology 
of the tumour. This classification had the following categories: classical, desmoplastic, 
medulloblastoma with extensive nodularity, anaplastic variant and large cell variant. (14) 
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Classic medulloblastoma is a highly cellular tumor composed of diffuse masses of small, 
undifferentiated oval or round cells. Some medulloblastoma show neuronal, glial and other 
differentiation. Neuronal differentiation is manifested by neuropil and rosette 
formation. Reticulin-free nodules are the characteristic feature of the desmoplastic variant 
of medulloblastoma.   
 
Figure No.1: Photomicrograph of medulloblastoma  with classic histology  
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Figure No.2: Photomicrographs demonstrating Homer Wright rosettes in medulloblastoma 
 
 
Desmoplastic medulloblastoma demonstrates tightly packed cells with neuronal/ astrocytic 
differentiation. (5) Medulloblastoma with extensive nodularity, on the other hand is 
characteristically described in the WHO 2007 guidelines as being “different from the 
desmoplastic nodular variant in exhibition of markedly lobular architecture with markedly 
decreased inter nodular reticular-free substances.”  (15) 
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Figure No.3: Photomicrograph  of desmoplastic medulloblastoma: showing  the nodular 
pattern 
 
Figure No.4: Photo micrograph of MBEN variant  
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Cells belonging to the large cell variant of medulloblastoma have nuclei which are large and 
pleomorphic with prominent nucleoli, with abundant cytoplasm according to Louis et al. 
(16) 
 
Figure No. 5: Photomicrograph showing large cell variant of medulloblastoma with  large, 
pleomorphic nuclei  with prominent nucleoli, and abundant cytoplasm.  
 
Louis et al also elaborates as to how anaplastic medulloblastoma has large tumour cells with 
prominent nucleoli, abundant mitotic figures and multiple apoptotic bodies. (14) 
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Figure No. 6: Photomicrograph of anaplastic variant of medulloblastoma showing large 
tumour cells with prominent nucleoli 
 
Massimino et al in their study have shown how those with desmoplastic and classical 
variants had a better prognosis when compared with those who had anaplastic and large 
cell variants.(17)This study looked at a total of 125 patients over 10 years, who received 
standard treatment as per protocol, before more aggressive treatment was commenced for 
anaplastic variants. For those with medulloblastoma with desmoplastic variant, the overall 
survival at 5 years was 81 %, and for the MBEN variant, the overall survival was 91.3 %. The 
overall survival for the anaplastic variants for the same duration, however, was only 44.4 %, 
which was statistically significant. Further, studies by Verma et al, which are based on data 
derived from the Childhood Brain Tumour Consortium database have also shown a clear 
19 
 
association between longer disease free survival among those with desmoplastic 
medulloblastoma, when compared with those with all other subtypes. This study looked at 
556 medulloblastoma patients with the comparison groups being desmoplastic 
medulloblastoma, and medulloblastoma of other subtypes. The histological features 
associated with good prognosis according to this study(with statistically significant 
differences, were the presence of high density fine fibrillary stroma, and the presence of 
nodular and ball like appearance as well as absence of necrosis and prominent nucleoli. (5) 
 
Anaplastic medulloblastoma was shown to have an aggressive course and worse outcome in 
studies conducted by Eberhart et al. This study looked at 67 medulloblastoma cases from 
the John Hopkins database, and the pathology tissue specimens which fit the criteria for 
further histochemical analysis were identified and studied in detail. C- myc expression had 
statistically significant associated with shorter survival, as was severe anaplasia.  Survival 
rates were increased with lower n-myc and higher TrKc expression, however this difference 
was not statistically significant.(18)Caputy et al retrospectively studied the clinical, histologic 
and biologic features of 54 medulloblastoma which were treated in Children’s Hospital 
National Medical Centre and Georgetown University Medical Centre, Washington D.C. found 
that tumours which showed necrosis, i.e, those with high turnover rates, usually anaplastic 
variant, had a statistically significant poorer outcome when compared with the rest. This 
study also showed a higher proportion of recurrence free disease among those who had 
well differentiated tumours.(19)Leonard et al in their studies of the large cell/anaplastic 
variant and medullomyoblastoma showed worse prognosis and higher rates of CSF 
dissemination among them when compared to the other histological variants of 
medulloblastoma.(20) 
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(3)Classification based on molecular subgrouping: 
Identification of various histological types as prognostic markers was found to be 
inadequate, as it was found that certain patients did well, inspite of residual tumour post-
operatively and even metastases at the time of diagnosis, whereas certain others did badly 
irrespective of extensive aggressive treatment. This lead to the realisation that there were 
other, more important and more significant markers of the nature of the disease and the 
prognosis, other than histology.(21)  The search for better classification methods, which 
were more prognostic in nature was sought as it was found that even though survival rates 
had increased probably due to better and more aggressive treatment, the survivors suffered 
significant sequelae in the form of cognition deficits, hearing loss, endocrine insufficiencies 
etc. The consensus among paediatric oncologists, therefore, was to step down therapy 
accordingly for tumours with an overall better prognosis to decrease the morbidity of 
sequelae in survivors, as evaluated by Oyharcabal Bourden et al.(22) However, the 
histological classification was not sufficient to accurately predict the course of the tumour.  
Transcriptional studies on medulloblastoma have been happening over the last decade, and 
it was finally decided during the Boston Consensus conference of 2010 to classify 
medulloblastoma based on their immunohistochemical properties into 4 subgroups: 
WNT(wingless), SHH(sonic hedgehog), Group 3 and Group 4.  Each of these subtypes have 
distinct demographics, clinical presentation, associated genetic abnormalities as well as final 
outcome, as detailed by Taylor et al in their landmark paper in Acta Neuropathologica.(6) 
With the help of immunohistochemical markers, the tumour can be divided into these 4 
subgroups, which will not only help in prognostication, but also in targeted therapies, such 
as SHH inhibitors for sonic hedgehog group. (23) 
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Molecular subgroups of medulloblastoma and their characteristics: 
(a)  WNT subgroup: 
Ellison et al have shown that WNT subgroup is seen in older children and young adults. (24) 
The histology seen in tumours of this subtype is usually classical, and very rarely large cell 
anaplastic type. There is no gender preponderance. Metastatic disease is rare at the time of 
presentation. The genetic mutation involved in this subtype is in the CTNNB1 gene 
mutation, affecting the WNT pathway. MYC gene amplification is seen commonly with this 
subtype, and the prognosis is good for this subtype. Since the CTNNB1 mutation is 
responsible for this subgroup, WNT pathway has a strong association with Turcot syndrome, 
which shares the same mutation, and is associated with familial adenomatosis polyposis of 
the colon, skin pits and skeletal abnormalities in addition to medulloblastoma.(25)About 15 
% of those with Turcot syndrome have WNT pathway medulloblastoma according to Ellison 
et al who studied this in detail. A strong association between monosomy 6 and WNT 
pathway has also been noticed by Ellison et al who studied the molecular and clinico-
pathological correlation between the various subgroups. (26) 
(b) SHH subgroup: 
Ellison et al have described how the sonic hedgehog group equally affects males and 
females, with bimodal incidence among infants and adult.(24)These tumours commonly 
exhibit desmoplastic histology. Metastases are uncommonly seen at the time of 
presentation. SMO, SUFU and PTCH1 mutations are commonly seen in this type, affecting 
the SHH pathway. MYCN gene amplification is the hallmark of this subgroup. Prognosis is 
good for affected infants, and intermediate for adults. Nevoid basal cell carcinoma 
syndrome, also called Gorlin syndrome, which is associated with basal cell carcinoma of the 
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skin, odontogenic keratocysts, other skeletal abnormalities, etc is found in association with 
this subgroup.  
 
(c) Group 3: 
Group 3, commonly involves infants and younger children. Large cell anaplastic and classical 
type of histology are commonly associated with this subgroup. According to the Boston 
Consensus Conference, this subgroup usually presents with metastatic disease, and overall 
prognosis is poor in all age groups. Strong MYC amplification is characteristic of this 
group.(6) 
 
(d) Group 4: 
Group 4, shows a strong male predominance. This type commonly occurs among younger 
adults as compared to infants and older people. Like Group 3, this group also commonly has 
large cell anaplastic and classical histology, and is frequently metastatic at the time of 
diagnosis. Prognosis is intermediate. This group shows minimal MYC or MYCN 
amplification.(6) 
       The table given below summarises the common features associated with the molecular 
subgroups of medulloblastoma: 
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       Table No 1: Characteristics of the 4 molecular subtypes of medulloblastoma 
 WNT SHH Group 3 Group 4 
Age group Children, 
young adults 
Infants, adults Infants, 
Adolescents 
Adolescents 
Paediatric 
incidence 
10 % 30 % 25 % 35 % 
Peak Incidence Adolescents 
and young 
adults 
Infants and young 
adults 
First decade of 
life 
Adolescence 
Histology Classic Desmoplastic/nodular Classic and 
large cell 
anaplastic 
Classic 
Cell of origin Lower rhombic 
lip progenitors 
Granule neuron 
precursors from 
External Granular 
Layer, and sub-
ventricular zone stem 
cells 
Granule 
neuron 
precursors 
from external 
granular layer 
Unknown 
Gender 
Predilection 
Male = Female Male = Female Male: Female 
2:1 
Male: Female 
2:1 
Radiological 
characteristics 
T2 FLAIR- 
hyperintense 
T2 FLAIR- 
isointense 
Ring enhancing 
lesions, areas 
of central 
T2 FLAIR-
hyperintense 
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necrosis 
Syndromic 
association 
Turcot 
syndrome 
Gorlin syndrome 
 
Unknown Unknown 
Associated 
common 
mutations 
CTNNB1, Wnt 
pathway 
mutations, 
Monosomy 6 
PTCH, SUFU, MYCN MYC 
amplification 
MYCN 
amplification 
Metastases at 
presentation 
Very rare Unusual Very frequent Frequent 
Prognosis Very good Good Poor Intermediate 
 
 
Overall, there is better prognosis if the tumour belongs to WNT or SHH subtypes rather 
Group 3 or Group 4, hence it is considered sufficient if the tumours can be categorised 
Into WNT, SHH or non WNT/non SHH (or Group 3 and Group 4) as shown by Ellison et al.  
As shown by the same study by Ellison et al, it is sufficient to use any two  immuno- 
histochemical markers to differentiate between WNT, SHH and non WNT- non SHH 
subgroups of medulloblastoma. 
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Table No. 2: Immunoreactivity of the various molecular subgroups:  
Molecular 
Group 
Immunoreactivity 
GAB1 β – catenin Filamin A YAP1 
SHH Cytoplasmic Cytoplasmic Cytoplasmic Nuclear  + Cytoplasmic 
WNT Negative Nuclear + Cytoplasmic Cytoplasmic Nuclear  + Cytoplasmic 
Non-
SHH/WNT 
Negative Cytoplasmic Negative Negative 
 
 
Figure No. 7: Photomicrograph of   medulloblastoma with immunopositivity for beta catenin  
Even though there are many studies world-over confirming the relationship between the 
molecular subgroups of medulloblastoma and their varied clinical presentation, course of 
illness and overall prognosis, there were very few Indian studies confirming the same. In this 
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study, we have used β-catenin and the histology of the various tumours for molecular 
subtyping medulloblastoma into WNT, SHH and non WNT-non SHH groups. 
Risk stratification: 
Risk stratification for any disease is required for prognostication, and it is also the deciding 
factor in deciding the aggressiveness, duration and the modalities of treatment. The initial 
classification system was proposed by Chang et al in 1969, which was a modification of the 
TNM scoring system which was used for other solid organ tumours.(27) The scoring system 
is as follows: 
Chang scoring system for medulloblastoma(28) 
(a)Tumour stage 
 T1: tumour diameter <3cm, involving one structure in posterior fossa 
 T2: tumour diameter <3cm, involving two or more structures posterior fossa structures 
 T3a: tumour diameter >3cm, involving two or more structures posterior fossa structures 
 T3b: tumour involving floor of the 4th ventricle 
 T4: tumour spreading out of the 4th ventricle or presence of severe hydrocephalus 
(b) Metastases stage 
 M0: no tumour cells in cerebrospinal fluid (CSF) 
 M1: presence of tumour cells on CSF cytology 
 M2: tumour seeding in intracranial CSF pathways 
 M3: tumour seeding in spinal CSF pathways 
 M4: systemic spread 
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According to the Chang system, a higher T stage or M stage prognosticates a worse outcome 
in terms of survival. This was shown by Zeltzer et al (28)when their study on 203 patients 
with medulloblastoma showed a significant survival advantage among those with non 
metastatic disease when compared with those with metastatic disease. Phi et al in their 
study on CSF metastatic disease in medulloblastoma also showed that metastatic disease 
played an important role in determining the survival.  
 The next stratification which came into use was the MAPS scoring system, which as the 
name indicates, stands for Metastases, Age, Pathology/ histology and Surgery(degree of 
resection).  This stratification method was used in the 1980s, but was less popular than the 
Chang system of classification. Following this, the next scoring system to come into use was 
the one elaborated by Sure et al.(29) This method came into vogue in the 1990s, after 
publication of the results of a study on 66 patients with medulloblastoma who were treated 
at a single centre using similar surgical methods. The comparison was based on the patient 
survival as analysed by Kaplan-Meier survival analysis studies. The total score from this 
system is 20, with the three prognostic groups being those with scores<=6, 7-13 and more 
than 13. The higher the scores, the better the patient’s prognosis according to this study. 
The parameters used and the scores are provided below(29) 
Sure scoring system: 
 
Parameter  Subgroup  Scoring Number               
Age   >10 years   2 
   0-10 years   0 
Location  2a    3 
   1a    2 
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   2b    1 
   1b    0 
Resection  Total    4 
   Subtotal   2 
   Partial    1 
   Biopsy    0 
Metastases  No    3 
   Present   0 
 
Histology  Desmoplastic   2 
   Classical   0 
 
Where    location codes are 
1a = Medial with no infiltration 
1b = Medial with infiltration 
2a = Lateral 
2b = Cerebellopontine angle 
 
Based on the scores, three distinct classes were formed, with the one having the highest 
score having the best prognosis.  This study found that their patients who were older than 
ten years at the time of diagnosis had a better survival rate when compared to those who 
were less than ten years of age at the time of diagnosis(p <0.01). Patients with a more 
lateral tumour location also did better than those who had a midline tumour, or those with 
brainstem infiltration (p<0.05). Total surgical resection was also associated with a more 
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favourable outcome when compared with subtotal resection (p<0.01) or partial excision 
(0.001).  Patients who had a metastatic disease at the time of presentation also had a worse 
prognosis than those with non metastatic disease (p<0.001). Desmoplastic histology also 
provided a favourable outcome when compared with classic histology (p<0.01).  
 
Current risk stratification: 
The current risk stratification for medulloblastoma as proposed by Packer et al is based on 
the following factors: age at presentation, degree of tumour resection, histology of the 
tumour and the presence of metastasis (spinal/distal). Of these, age more than 36 months 
at the time of diagnosis, complete resection of tumour, absence of metastasis and 
desmoplastic histological variant are associated with good prognosis. (30) Kortmann et al 
looked at the efficacy of neo-adjuvant chemotherapy before radiotherapy, in comparison 
with standard RT with concurrent vincristine followed by 8 cycles of chemotherapy 
regimen.(31) 137 children were randomised into these two groups, and the results were 
analysed in terms of toxicity of treatment, survival and prognostic factors, both positive and 
negative. This study found that in irrespective of treatment regimen, those who were 
between 1.5-3 years did badly, as those with subtotal resection of tumour, thereby 
confirming the current risk stratification system. Zeltzer et al did a randomised control 
Phase III study on 203 children with medulloblastoma, on the efficacy of “ 8 drugs in one 
day” before radiotherapy and after radiotherapy, in comparison with Radiotherapy followed 
by chemotherapy with vincristine, lomustin, cisplatin and prednisolone.(28) Stratification of 
disease was done using metastatic stage and location of the tumour, as proposed by the 
Chang system. This study showed the four drug regimen to be superior to the 8 drugs in one 
day regimen in terms of overall survival as well as event-free survival. In addition, this study 
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also proved that for children with non metastatic disease, age more than 3 years and 
residual disease less than 1.5 cm2 are both positive prognostic factors.  
 
Prognostication using biologic markers is being evaluated in many centres.  Ellison et al 
studied the presence of  β-catenin as a favourable prognostic marker, and found that 
nuclear beta catenin positivity is associated with favourable outcome.(32)Similar 
conclusions were drawn by Fattet et al, however it is still not universally acceptable to step 
down therapy based on the presence of β-catenin positivity alone.(33) 
Shih et al also showed isochromosome 6(loss of one copy of chromosome 6) has a good 
prognosis in the presence of β-catenin positivity.(34)Gilbertson et al studied the effect of a 
group of biomarkers on disease prognosis and found high ERbB2 receptor expression and 
isolated chromosome17 p loss to be associated with bad prognosis. (21)Pan et al, on the 
other hand, found isochromosome 17q to be a poor prognostic factor in high risk 
disease.(35)Further, studies by Eberhart et al at John Hopkins Institute found TrkC 
amplification to have positive prognosis, as against n-myc and c-myc amplifications, which 
were found in association with tumour anaplasia and worse prognosis.(18) 
 
Shih et al in their studies on prognostic biomarkers, found different prognostic factors for 
each of the 4 molecular subtypes. (34)Their findings are summarised in the table below: 
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Table No. 3:   Prognostic association of biomarkers with molecular subtypes 
 Biomarker Prognosis 
WNT Isochromosome 6 Good prognosis 
SHH Loss of chromosome 14q 
GLI2 amplification 
GLI2 amplification + 
chromosome 14q- 
Chromothripsis 
Poor prognosis 
Poor prognosis 
 
Poor prognosis 
Poor prognosis 
Group 3 Isochromosome 17q 
MYC amplification 
Chromosome 8q loss 
Chromosome 1q gain 
Poor prognosis 
Poor prognosis 
Good prognosis 
Good prognosis 
Group 4 10 p loss +loss of 
chromosome 11 
Chromosome 10p loss + 
gain of chromosome 17 
MYCN amplification 
Good prognosis 
 
Good prognosis 
 
No effect 
 
The above table shows how prognostic factors can vary between subgroups as well; hence 
they should be taken in the context of the subgroup and the histology, and not in isolation. 
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Treatment of Medulloblastoma 
Treatment of medulloblastoma requires a multidisciplinary approach. Lafay-Cousin et al 
elaborated how the standard of care treatment for medulloblastoma consists of total/ near-
total surgical resection followed by radiotherapy and adjuvant high dose multi-agent 
chemotherapy.(36) However, there is significant short term as well as long term morbidity 
associated with disease as well the treatment, hence it is essential to stratify the disease 
prior to commencement of treatment.  
Pre-treatment assessment 
Pre-treatment assessment includes careful consideration of age of the patient, location of 
the tumour along with resectability and metastatic stage.    MRI is currently considered as 
the gold standard of imaging of the brain and spine to confirm disease, delineate the extent 
of the disease and to look for leptomeningeal enhancement.  Meyers et al were the first to 
describe the MR features of medulloblastoma, which included the classic location, high 
propensity for hydrocephalus, and better demarcation of peri-lesional oedema with the use 
of contrast enhancement. (37) 
MRI features for distinguishing between the molecular subgroups: 
Perreault et al have described very precisely the MRI features of the different molecular 
subgroups, which can be used as surrogates for the immunohistochemical markers pre-
operatively(38).  This study looked at 47 patients, who were treated at the Stanford 
University, all of who had pre-operative imaging in the form of MRI as well as tumour 
histology done post-operatively. 3 separate neuro-radiologists, who were not aware of the 
histology assessed the MRI images separately. Validation of the MRI features of the 
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separate subtypes were done by assessing another cohort of 52 paediatric medulloblastoma 
patients from the hospital for Sick Kids, Toronto.  
The MR imaging features that were analysed by Perreault et al were the following: location 
of the tumour, the pattern of enhancement, presence of any cysts/ cavities, any areas of 
haemorrhage/ mineralization, any evidence of intracranial or leptomeningeal seeding, the 
margins of the tumour and any areas of necrosis as evidenced by ring-enhancement.  This 
study showed how WNT tumours were usually seen in the cerebellar peduncle, or in the 
cerebello-pontine angle.  Location of the tumour in cerebellopontine angle was associated 
with a positive predictive value of 100 % for WNT tumours. SHH tumours on the other hand, 
were commonly seen along the cerebellar hemisphere.  Group 3 and group 4   tumours are 
more commonly located within the fourth ventricle and usually do not show any 
enhancement with contrast. Ill defined tumour margins were also documented as a 
characteristic feature of Group 3 tumours.  The presence of cystic areas, necrosis, 
mineralised areas and areas of haemorrhage were not found to have any statistically 
significant association with any of the molecular subgroups. Considering the fact that MRI 
forms the gold standard of diagnosis of medulloblastoma, and is a standard of care 
diagnostic procedure, this can be used as a pre-op surrogate for molecular subgroups in the 
future, especially keeping in mind how expensive tumour markers are.(38) 
CT myelography as described by Meyer et al, which was being used to detect 
leptomeningeal involvement in the 1990s is not in vogue anymore. The timing of 
investigations to detect metastases is also crucial.(37) 
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Metastatic workup 
  The two investigations which are commonly used for the detection of leptomeningeal 
spread are MRI spine and CSF cytology. Harrison et al  in their study regarding use of these 
two modalities, found cytology to be as good as MRI spine, and that there was no 
superiority in obtaining a sample from the cisterna magna as compared to CSF obtained by a 
lumbar puncture. (39)Fouladi et al did a comparative study to look at which of these two 
modalities is more superior at detection of leptomeningeal metastases. The results of this 
study showed that both were invaluable, and both could miss up to 14 % of metastases if 
done singly, hence the gold standard is still MRI spine plus CSF cytospin for malignant cells. 
(40) 
The other issue commonly faced while diagnosing metastases was the timing of these 
investigations. For a long time, it was a common recommendation that these investigations 
be done after 3-4 weeks of surgery, to avoid spurious results due to blood stained cytospin 
smears which would be unsatisfactory for evaluation and to avoid missing leptomeningeal 
thickening and clumping due to blood in the cisterns.  However, since radiotherapy starts as 
early as 2-3 weeks after surgery, the current recommendations by Raleigh et al are that MRI 
spine for detection of leptomeningeal metastases be done pre-operatively, to prevent post-
op artefacts resulting in either over-diagnosis or under-diagnosis as a result of obscuration 
of the  deposits by blood. (25) Cytology is advocated at least 2 weeks after surgery, to 
prevent false positive results. On the other hand, imaging of the brain to look for post-op 
residual lesions should be done within 72 hour of surgery so that granulation tissue does not 
obscure any residual lesions. 
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Treatment guidelines for medulloblastoma have changed over the years with new advances, 
however the basic principle remains the same- it is a multidisciplinary approach, utilising 
neurosurgical expertise for near total excision, followed by adjuvant chemotherapy as per 
protocol and radiotherapy as per protocol. Pollack et al reviewed this multidisciplinary 
approach towards medulloblastoma and found that risk adapted treatments for individuals 
seem to be the current best option for medulloblastoma.(41) 
Pre-operative CSF shunt surgery 
Due to the fact that medulloblastoma arises most commonly around the fourth ventricle, 
this tumour has a propensity for hydrocephalus. Albright et al had shown how children who 
underwent surgical shunting for increased ICP did better in the post-operative period, with 
significantly decreased mortality than those who did not have a shunt surgery.(42) 
Schweitzer et al has however raised the possibility of extraneural metastases following a 
ventriculoperitoneal shunt. (43)However, in a scenario with an imminent risk of tonsillar 
herniation, or a poor sensorium as a result of raised ICP is present, an emergency CSF 
drainage is advocated. Muzumdar et al have shown how one-third of those with posterior 
fossa tumours will need a pre-operative CSF diversion, one third will not need any diversion, 
and one third will benefit from early surgery alone without any CSF shunt.(23)  
The various shunt procedures include ventriculoperitoneal shunts, ventriculoatrial shunts 
ventriculo-pleural shunts etc. However, what is preferred nowadays, in the presence of a 
functional CSF absorption pathway is a third ventriculostomy, which can be done intra-
operatively as well and has less complications according to Muzumdar et al.(23)When the 
decision to do a shunt surgery is considered, the possibility of complications such as shunt 
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infection, blockage, etc should also be considered, and weighed against the benefits and 
necessity of the shunt surgery. Often anti-oedema measures and early surgery are enough 
to manage hydrocephalus and its associated complications. 
Surgical management 
Following appropriate pre-operative workup and stabilization as detailed before, surgical 
excision is the next in line as treatment of medulloblastoma. Total or near total excision of 
the tumour is associated with the best outcome according to Lafay-Cousin et 
al.(36)According to Packer et al, residual disease of <1.5cm2 is considered as standard risk 
disease. (30)However, extensive resection of the tumour in an attempt to achieve as much 
local control of the disease may lead to significant neurological deficits post-operatively. 
Post-operative complications- posterior fossa syndrome 
The most important and common consequence of extensive resection is posterior fossa 
syndrome(PFS), also known as cerebellar mutism. Pitsika et al have explained how the term 
cerebellar mutism syndrome (CMS) is used to describe a group of symptoms caused by a 
cerebellar lesion, which includes muteness, ataxia, hypotonia, dysarthria and irritability. 
Posterior fossa syndrome is a broader term that includes cerebellar mutism as well as 
movement disorders (ataxia and hypotonia) and a wide spectrum of neurobehavioral 
abnormalities.(44) Cerebellar mutism may be seen in upto 25 % of children operated for 
medulloblastoma according to Muzumdar.(23). This is thought to have occurred as a result 
of interruption of the dentato-thalamo-cortical pathway as a result of extensive surgical 
resection.  Though these children improve usually improve within 2-3 months of surgery, 
reports of a certain degree of neurological sequelae have been reported by Pitsika et al.(44)   
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Various risk factors have been postulated for cerebellar mutism by Doxey et al and Grill et 
al, the important ones being midline location of the tumour, brainstem involvement and a 
more aggressive and invasive tumour.(45)(46) The others implied commonly are a younger 
age at diagnosis, a pre-existing language impairment, radical tumour excision,  larger 
tumour size and vermian incision during surgery.  The core characteristics of cerebellar 
mutism are that it is delayed, I.e, the onset is usually after 1-6 days of normal speech post-
operatively, and that it is transient, lasting from a few weeks to 6 months. Speech is usually 
the first symptom to recover, followed by oropharyngeal apraxia (refusal to or inability to 
swallow inspite of intact gag reflex). The irritability and emotional lability are next to 
recover.  
 Wells et al looked at the imaging studies done in set of patients who were operated on for 
posterior fossa tumours, and subsequently developed posterior fossa syndrome, and at 
controls that underwent surgery and did not develop posterior fossa syndrome in an 
attempt to identify radiological features of posterior fossa syndrome. (47) They found that 
pre-operatively, there was no difference between the two groups in terms of tumour size, 
peri-lesional oedema or hydrocephalus. However, brainstem invasion was shown to be 
statistically significant, as was cerebello-medullary angle involvement.  Among post-
operative images, middle and superior cerebellar peduncle oedema among those with 
cerebellar mutism was found to be statistically significant. A 1 year post-operative MRI in 
this cohort showed those who had had cerebellar mutism to have more significant gliosis or 
atrophy of total cerebellum, vermis and brainstem. Mean IQ was 16 points lower in patients 
with cerebellar mutism as well at the end of a 1 year period, showing long standing 
neurological sequelae. 
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 Long term follow up of children with cerebellar mutism by Robertson et al showed that 
they had problems in solving novel situations, decreased speed of speech, processing, and 
reasoning as well as decreased verbal initiation and significantly poor performance in 
reading, spelling, math, and working memory(48). All of these can affect schooling in the 
future.  Pharmacological therapy for posterior fossa syndrome has been attempted without 
much success, and counselling of parents as well as children is essential, to teach them 
compensatory strategies in order to decrease sequelae and the duration of disabilities. 
Other post-operative complications 
The other common post-operative complications are meningitis (septic as well as aseptic), 
CSF leak and pseudomeningocoele as shown by Muzumdar et al.(23)  Appropriate 
antibiotics and drainage procedures are advocated for the same. Gopalakrishnan et al did a 
study on factors necessitating post-op CSF diversion techniques and found that those who 
had a midline tumour, shorter duration of symptoms at the time of presentation (indicating 
more aggressive tumour), intra-operative EVD placement and post-operative 
meningitis/pseudomeningocoele had a higher chance of needing a post op CSF diversion 
surgery.(49)  Hyponatremia following surgery was studied by Williams et al, and was found 
to be common among those who had obstructive hydrocephalus, and among younger 
children.(50) Symptomatic hyponatremia was not uncommon, and was associated with 
increased neurocognitive sequelae later on according to this study.(51) 
Radiotherapy 
Radiotherapy forms an integral part of adjuvant therapy for medulloblastoma. However, 
radiotherapy, especially when given to an immature developing brain, often leaves behind 
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significant sequelae.  Hence most protocols try to avoid radiation in those younger than 3 
years of age according to the guidelines offered by Lafay Cousin et al.(36) This may vary 
according to the various protocols used, with HITKK92 not using RT at all, and relying on 
surgery, aggressive chemotherapy and second look surgery if needed, whereas Headstart I 
and SFOP guidelines advocate only salvage RT. According to Headstart II guidelines, RT is 
given only after 6 years of age, or for residual disease. All these measures indicate the 
awareness that has come regarding neurocognitive sequelae of radiotherapy to a young 
brain.  
 Geyer et al studied the effect of high dose chemotherapy alone, without the use of 
radiotherapy in infants with medulloblastoma and got survival results comparable with 
regimens which used radiotherapy, with less sequelae.(52)  Oyharcabal- Bourden et al 
studied the effect of reduced dose radiotherapy and standard chemotherapy in children 
with standard risk medulloblastoma, and found comparable results with those who received 
full dose of radiotherapy, thereby implying that for this low risk/standard risk disease, 
radiotherapy can be decreased within acceptable limits.(22) 
Radiotherapy for medulloblastoma involves two main areas- one is the tumour bed, and the 
other being craniospinal irradiation. On an average, the tumour bed site is given around 54 
Gy of radiation, within a radius of 1-2 cm of the primary tumour bed. Craniospinal 
irradiation delivers another 23.4-36 Gy of irradiation to the neuraxis according to Pollack et 
al.(41)  These high doses of radiation result in neurocognitive deficits in the treated children 
as shown by Robinson et al, with younger children and those receiving higher doses of 
radiation  having a higher chance of developing the same. This is the rationale for avoiding 
radiotherapy in those younger than 3 years. 
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Studies by Oyharcabal- Bourden et al etc have looked at stepping down treatment for 
standard risk medulloblastoma with reduction in radiotherapy in an attempt to decrease the 
long term sequelae of the aggressive treatment involved for medulloblastoma.  The 
researchers in the above study had concluded that should staging for prognostication be 
carried out promptly and precisely, then reduced radiation can be used successfully for 
treatment of standard risk medulloblastoma.(22) 
Adjuvant chemotherapy 
Adjuvant chemotherapy forms a vital part of the treatment of medulloblastoma. Most 
regimes use concurrent vincristine weekly with radiotherapy, and thereafter chemotherapy 
for another 6-8 cycles.  Common chemotherapeutic drugs used include vincristine, lomustin, 
cisplatin, carboplatin, procarbazine, cyclophosphamide and etoposide. Many regimes have 
now included G-CSF as part of the regime in view of significant cytopenias induced by the 
chemotherapy, as shown by Geyer et al.(52) Regimens used in the past include the infamous 
“ 8 drugs in a day” regimen, which had intolerable side effects as shown by Oyharcabal 
Bourden et al.(22) 
 
Chemotherapy adds on further morbidity in the long run, in the form of hearing loss, renal 
tubular dysfunction, etc, which will be described under late effects. Monitoring for drug 
toxicities, therefore form an integral part of all chemotherapy with strict monitoring of 
white cell counts, renal functions, hearing, electrolyte status etc during as well as between 
chemotherapy cycles, with appropriate management of any imbalance promptly to avoid 
any untoward events. Chemotherapy regimens as well as drugs are changed if toxicity is too 
high with the current regimen. 
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Late effects of treatment 
Surgery, radiotherapy as well as chemotherapy have associated long term morbidity. 
Extensive resection leads to posterior fossa syndrome as described by Doxey et al, with 
residual neurological deficits as described by Wells et al(45)(47).The use of various CSF 
shunts as well have their own associated complications, such as shunt infections, shunt 
malfunction and the possibility of extra- neuraxial metastases as elaborated by 
Gopalakrishnan et al, and Schweitzer et al(49)(43). 
Craniospinal irradiation is associated with neurocognitive deficits and long term neuro-
endocrine sequelae. Christopherson et al looked at the late toxicity in 53 patients who had 
been treated for medulloblastoma, 41% of the survivors had grade 3 or more toxicity as per 
the NCI common Terminology Criteria for Adverse Events, Version 4.0. These included 
hearing deficit requiring intervention in 20.5% and cognitive impairment prohibiting 
independent living in 18%. 4/53 developed secondary malignancies and 3/53 died from 
treatment related complications severe cerebral oedema, radionecrosis and fatal secondary 
malignancy. (53) 
Knight et al looked at the working memory in children with medulloblastoma. 167 children 
were included in the study and serial assessments of working memory were done at 
predetermined time points for 5 years. They found a statistically significant decrease in the 
age standardized scores, and posterior fossa syndrome was consistently associated with a 
poorer working memory. Younger age and higher treatment intensity were associated with 
a greater negative change in working memory. (54) 
Younger children may sustain more severe damage due to the immaturity of the brain at the 
time of irradiation. There is decline in intellectual ability, with difficulty in motor tasks, 
42 
 
perceptual abilities, memory, executive functions as well as verbal ability.  In a study of 
brain tumour survivors who were treated with radiation, done by Packer et al in 2001, in 
comparison to their disease free siblings, survivors of brain tumours had more significant 
sequelae.  There was a relative risk of 17.5 of developing hearing difficulty, and 49% 
reported having difficulty with co-ordination and 26 % reported difficulty with motor skills. 
Seizure disorder was present in 25 % of the survivors(55). In yet another study by Ris et al, 
43 children who had undergone treatment for medulloblastoma with reduced dose of RT 
and adjuvant chemotherapy were evaluated longitudinally for cognitive functioning.  
According to this study, there was a decline in the domains of Full Scale Intelligence 
Quotient (FSIQ), Verbal IQ (VIQ) and non-verbal IQ (NVIQ), by -4.3, -4.2 and -4.0 points 
respectively per year. Those who are younger than 7 years at the time of radiation had a 
more significant decline in NVIQ, and females had a statistically significant decline in VIQ 
when compared to males. It was also shown that those who had a higher baseline IQ had 
more of a decline as well. (56) 
Robinson et al, while looking at the neuro-cognitive sequelae of posterior fossa paediatric 
tumours, found significant deficits in the indices of neuro-cognitive functions such as overall 
cognitive functioning, academic achievement, attention/concentration, executive function, 
information processing speed, psychomotor skills, verbal memory, visuo-spatial skills, visuo-
spatial memory and language. (57) This indicates that the deficits are encompassing than 
thought previously, and cognitive assessment, follow up and appropriate training and 
rehabilitation might be necessary for all survivors of childhood brain tumours. 
Knight et al also looked at the hearing disabilities acquired as a result of cisplatin toxicity.  
Factors increasing the risk for cisplatin ototoxicity include a cumulative cisplatin dose of 360 
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mg/m2 or greater, associated renal dysfunction, and use of other ototoxic medications 
during treatment such as loop diuretics, aminoglycoside antibiotics, carboplatin etc. (58) 
Cranial irradiation before cisplatin therapy also increases risk of hearing loss. 
Cisplatin toxicity typically starts at high frequency levels, and progresses to involve lower 
frequencies as well.  Tinnitus may be found in association with the hearing loss.  Hearing 
loss usually begins after the 3rd cycle of chemotherapy according to Knight et al, hence 
hearing screening has accordingly been incorporated into most protocols after the third 
cycle. But what was most striking from this study was that the hearing loss can progress 
even after completion of therapy. Therefore periodic monitoring is required after 
completion of treatment during follow up visits as well.  
 Brock et al studied the effects of platinum based chemotherapeutic agents, i.e, cisplatin 
and carboplatin on hearing.(59) Based on these studies, oto-protective measures, such as 
reduction of total dose of drugs, and gradual escalation of doses have been planned for all 
regimens using these drugs, however these may affect the efficacy of the drug with regard 
to the tumour. The SIOP guidelines for ototoxicity classify hearing loss due to drugs as given 
below: 
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Table No. 4: SIOP ototoxicity scale 
SIOP Boston Ototoxicity Scale Grade Parameters 
0 <20 dB HL at all frequencies 
1 > 20 dB HL (i.e., 25 dB HL or greater) SNHL 
above 4,000 Hz (i.e., 6or 8 kHz) 
2 >20 dB HL SNHL at 4,000 Hz and above 
3 >20 dB HL SNHL at 2,000 Hz or 3,000 Hz and 
above 
4 >40 dB HL (i.e., 45 dB HL or more) SNHL at 
2,000 Hz and above 
 
This scale is more functional and predicts the need for hearing aids and special training, as 
opposed to the conventional measures of hearing loss. Brock et al also advocates the use of 
anti-oxidants such as NAC which protect against the ototoxic effects of the drugs, and do 
not decrease their efficacy on the tumours.(59) The other drugs under consideration as 
otoprotectors as STS, a thiol reducing substance, amifostine, D-methionine and ebselen. 
However, none of these have been approved for human use yet.    
Knight et al states that the impact of hearing loss depends on the child’s age, the severity of 
the hearing loss and affected frequency range, the timing of intervention, and other 
factors.(58) Speech and language development may be affected when hearing loss is 
acquired in early childhood. Older children and adolescents are at risk for reduced 
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educational achievement, social isolation, emotional difﬁculties, and decrease in health-
related quality of life.  
Guillaume et al also found a statistically significant association between CSF shunting and 
hearing loss.  They found that age, side of shunt, evidence of CNS dissemination, diameter 
of cochlear aqueduct, and treatment protocol did not have a significant effect on shunt-
related ototoxicity.(60) This is thought to be as a result of increased ICP prior to shunt 
surgery, as  changes in CSF pressure is thought to have an effect on cochlear physiology via 
endolymph expansion in the setting of a patent cochlear aqueduct. 
Arany et al and Yiao et al have shown the nephrotoxic effects of cisplatin in addition to its 
ototoxicity. (61)(62) The toxic effects of cisplatin are mainly evident on the tubules, and can 
be minimised by following the set guidelines- adequate prehydration, and maximum 
infusion for 24 hours.  Longer duration of infusion has been shown by Arany et al to have an 
association with increased toxicity.(61) Studies by Erdlenburgh et al have also drawn similar 
conclusions(63). These renal effects can be transient causing derangement of renal 
parameters and electrolyte imbalance, or can be long-standing. 
Vincristine, another chemotherapeutic drug which is commonly used in treatment of 
medulloblastoma, has been long known to have associated neurotoxicity as a predominant 
side-effect.  Gomber et al studied the neurotoxic effect of vincristine on Indian children and 
found that up to 50 % of Indian children treated with vincristine had side-effects, which is 
much higher than the rates reported from western studies.(64) Legha et al have shown that 
vincristine causes peripheral neuropathy, autonomic neuropathy and cranial nerve palsies in 
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addition to being life-threatening if administered intrathecally. This study also showed that 
liver dysfunction and pre-existing neurological dysfunction can worsen this.(65) 
 Gomber et al showed that though clinical improvement in the peripheral neuropathy may 
occur within the first few weeks, electrophysiological changes persist beyond 6 months and 
more, predicting that the effects are longer lasting than previously thought.(64) 
The endocrine effects of treatment include hypothyroidism, growth hormone deficiency, 
delayed puberty and SIADH. Gurney et al found that growth hormone deficiency is seen in 
almost all peripubertal children and upto 50% of all children treated with whole brain RT for 
medulloblastoma, with a relative risk of  277.8 when compared to healthy peers, with a 
relative risk of 86.1 with respect to growth hormone requirement for inducing puberty. 
(66)Ilveskoski et al studied growth impairment and effects of growth hormone 
supplementation in children who had been treated for central nervous system tumours.  
The results of this study showed the most marked loss of height velocity among those 
children who received craniospinal irradiation in addition to chemotherapy. (67) However, 
what was striking was that even those who hadn’t had any radiation to the hypothalamo-
pituitary axis also had growth retardation. Response to growth hormone therapy was 
impaired in those who had reached pubertal age, as compared to those who were 
prepubertal at the time of administration of growth hormone. This shows that growth 
monitoring is mandatory in all children treated with radiotherapy for medulloblastoma and 
growth hormone supplementation is often necessary.  
Hypothyroidism occurs as a result of radiation to the hypothalamic area as well as scatter 
radiation received by the thyroid during radiotherapy. Gurney et al showed that there is a 
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relative risk of 14.3 for developing hypothyroidism among survivors of childhood brain 
tumours when compared to their siblings.(66) Life-long thyroxine supplementation with 
frequent monitoring is warranted to prevent the consequences of hypothyroidism.Brandes 
et al reviewed the incidence of endocrine dysfunction among those treated for brain 
tumours, and advised screening for the following four main categories- GH deficiency, 
gonadal alteration, hypothyroidism and hyperprolactinemia(68). Routine screening for the 
above and prompt pharmacological therapy will remedy the undue and preventable effects 
of these endocrine dysfunctions. 
Alterations in sodium metabolism in the form of SIADH, cerebral salt wasting and diabetes 
insipidus occur as a consequence of surgery and radiotherapy.  Williams et al studied the 
incidence of post-operative hyponatremia and any identifiable risk factors for the same. It 
was found that approximately 12 % of those who underwent surgery had hyponatremia as 
defined as serum sodium <130 mmol/l.  Hyponatremia was symptomatic in most children 
with 21% having seizures, and 41% presenting with altered sensorium(50). Younger age at 
presentation and obstructive hydrocephalus were identified as two major risk factors for 
symptomatic hyponatremia by this study. It was also noticed that these children had a 
longer, more complicated hospital stay and a 6-fold increase in moderate to severe disability 
when compared with those who were matched for age and tumour location, without any 
hyponatremia.(51) 
In the latter part of treatment, cerebral salt wasting has been reported as a common cause 
for hyponatremia. Cerebral salt wasting usually subsided within 2-4 weeks according to 
studies by Papadimitriou et al, with appropriate supplementation of fludrocortisone.(69)  
48 
 
Carrascosa et al also advocate workup for hypothyroidism, mineralocorticoid deficiency and 
hypophyseal/ pituitary dysfunction in the presence of difficult-to-treat hyponatremia in CNS 
tumour survivors as these endocrine conditions are commonly seen in these children.(70) 
SIADH, another common cause for hyponatremia in children post treatment for CNS 
tumours, warrants fluid restriction and desmopressin supplementation.  The supervision of 
a paediatric endocrinologist for treatment of the above is advocated. 
Multiple cardiovascular complications have also been noticed in the post-treatment period 
of CNS tumours. Gurney et al studied the incidence of cardiovascular complications among 
those who had been treated for CNS tumours. There was a 40-fold increased risk of stroke 
among CNS tumour survivors when compared to their siblings. However there was no 
increased risk of arrhythmia and only a two-fold increase in the risk for angina when 
compared to their siblings according to this study. (66)Among the cases, those who 
underwent both chemotherapy and radiotherapy were three times as likely to have a stroke 
when compared to those who had only radiotherapy.  
 Bowers et al also confirmed the increased risk of stroke among childhood CNS tumour 
survivors in their study(71). Diller et al, in their study on chronic diseases found that not only 
was there an increase in endocrine diseases such as hypothyroidism, growth hormone 
deficiency and disorders of puberty, female survivors of CNS tumours were also more likely 
to develop obesity, especially if they were younger at the time of diagnosis and had received 
RT to the hypothalamic area.(72) This study also found an increase in cardiovascular events 
and neurological and neurosensory deficits. 
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Neglia et al from the Childhood Cancer Survivor group reported that new CNS tumours can 
occur following treatment for CNS malignancies.(73) Gliomas and meningiomas were the 
commonest tumours found in this study, with gliomas occurring after a mean of 9 years 
after diagnosis, and meningiomas after an average of 17 years.  Radiation exposure was 
found to be a significant risk factor for development of subsequent neoplasms in this study. 
Strodtbeck et al also studied the risk of subsequent cancer following  primary CNS tumours, 
and found that the tumour with the highest risk of a second malignancy was 
medulloblastoma/ PNET, with a relative risk of 4.31 when compared to 1.26 for all CNS 
tumours. (74)In addition to CNS tumours, tumours of the thyroid, GIT and bone have also 
been reported after completion of treatment for medulloblastoma according to this study. 
Leukaemias are another late event following treatment for medulloblastoma/PNET, thought 
the incidence is less compared to the other solid tumours. 
Lew et al studied the incidence of cavernomas secondary to radiation among the survivors 
of medulloblastoma. (75)31 % of the patients studied in this study developed cavernomas 
(imaging and histology proven). The incidence increased progressively with time. No 
significant correlation between gender, age at diagnosis, dose of radiation received or the 
source of radiation, and the risk of development of cavernoma was noticed. These lesions 
were found to have a benign course however, and did not need aggressive treatment. 
Prognosis and recurrence 
Over the last few decades, there has been a drastic improvement in the survival rates of 
children with medulloblastoma. This has been attributed to improved and early diagnosis, 
improved treatment modalities and surveillance. However, it is well-known that survival 
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rates depend on multiple factors, of which the current impetus is on favourable molecular 
subgroups. The National Cancer Institute (US) gives the prognosis according to age groups- 
among children more than 3 years of age with average risk, 5 year event free survival rate is 
up to 80%.   
Those with high risk disease who were more than 3 years at the time of diagnosis had a 50-
60 % survival rate according to this study. Infants with desmoplastic variant have upto 75 % 
survival rates with current treatment regimens, however there is only 40% survival rates 
among those with disseminated disease and among those who were less than 3 years at the 
time of diagnosis. Packer et al gave the 5-year disease-free survival rates to be 50% to 60% 
in patients with average-risk disease and 40% or less in patients with high-risk disease in the 
1990s.(76) However, in the last decade, the trend has changed and Packer et al, in their mor 
recent study have shown that among children with non-disseminated disease who were 
treated according to standard protocol with chemotherapy and radiotherapy, five- and 10-
year event-free survival rates were 81+/-2% and 75.8+/-2.3% respectively and overall 
survivals were 87+/-1.8% and 81.3+/-2.1%.(77)The chemotherapeutic regime, sex, race, 
gender or age at diagnosis did not have any impact on the event free survival rates.  Of the 
seven patients in this cohort who relapsed after 5 years, 4 had local relapse, 2 had local plus 
supratentorial disease, and 1 had supratentorial disease alone. Fifteen patients developed 
secondary tumours as a ﬁrst event at a median time of 5.8 years after diagnosis. All non-CNS 
solid secondary tumours occurred in regions that had received radiation. This studied 
showed the cumulative 10-year incidence rate of secondary malignancies to be 4.2% (1.9%–
6.5%).  It also concluded that few patients with medulloblastoma will relapse ≥5 years post-
diagnosis, and that relapse will occur predominantly at the site of the primary tumour. 
51 
 
Rutkowski et al studied the prognosis of medulloblastoma treated between the years 1987-
2004, among the various histological subgroups and found that 8-year event-free survival 
(EFS) and overall survival (OS) were 55% and 76%, respectively, among those with 
desmoplastic/nodular medulloblastoma or medulloblastoma with extensive nodularity. 
(78)These rates came down significantly to 27% and 42%, respectively for children with 
classic medulloblastoma. In children with large cell anaplastic medulloblastoma, the same 
rates were a dismal 14% and 14%. These values were statistically significant, as far as 
prognosis in relation to histology was concerned. 
Raleigh et al showed how the molecular subgroups played a major role in determining the 
prognosis of medulloblastoma.(25) This study gives the survival rates to be approximately 
95%, 60-80%, 40-50% and 75% for WNT, SHH, group3 and Group 4 respectively.  This wide 
variation clearly illustrates the major role played by molecular subgrouping in prognosis of 
medulloblastoma. 
Quality of Life (QOL) 
As shown above, with current therapy, event free survival rates for average risk 
medulloblastoma is 75-80%. However these survivors have significant late effects of therapy 
which are likely to affect their quality of life. These include medical problems such as 
hypothyroidism, hyponatremia, pan-hypopituitarism, etc, in addition to hearing loss, 
cognitive difficulties, etc as described before. Brinkman et al in their studies found an 
increase in suicidal ideation among survivors of paediatric brain tumours.(79)  Mulhern et al 
also found significant cognitive difficulties among survivors of brain tumours, with younger 
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children, higher radiation exposure and female sex being significant risk factors for more 
rapid decline in cognition. (80) 
Maddrey et al studied the cognition, functional outcome and quality of life of 
medulloblastoma survivors in the second decade after treatment.(81) They found that there 
was significant impairment in all domains, including attention, memory, visuo-spatial 
abilities, motor functioning, language, and executive functioning. Signiﬁcant impairments 
were also present in all psychosocial domains examined, including employment, ability to 
drive an automobile, participation in normal education, independent living, and dating and 
interaction.  What was most interesting in this study, however, was that the quality of life 
scores, as reported by both survivors and their caretakers, were within the normal range. 
This indicates that though survivors of childhood medulloblastoma have significant deficits 
in a wide-range of neuropsychological functional domains, the survivors and their families 
do not report an impaired quality of life.  
Johnson et al had also studied the quality of life of survivors and found similar data, with 
none of the survivors scoring more than 90 on Intelligence Quotient assessment, and 78 % 
of the respondents having some degree of learning disabilities(82).  These studies show the 
effects of therapy for medulloblastoma on the cognition and quality of life of survivors, and 
advocate reduction of radiotherapy where feasible.  
Frange et al assessed the outcome of medulloblastoma survivors in multiple domains using 
self-reported questionnaires using Health Utility Index.(83) At a median follow up duration 
of 14.4 years from the time of diagnosis, this study found frequent late sequelae including 
neurological impairment and endocrine dysfunction. Psychosocial functioning was also 
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impaired in the majority of survivors. None of the males in the study had children, and only 
three of the females had offspring, thereby raising the possibility that the alkylating agents 
used for chemotherapy might be responsible for infertility among survivors as well. Female 
survivors had less difficulty socialising as compared to the male survivors.  Early intervention 
might be helpful in decreasing the neurocognitive sequelae among survivors. 
Instruments to measure QOL need to be multidimensional, assessing physical, mental, social 
and psychological aspects of well-being. Paediatric Quality of life inventory (peds QL) has 
been widely used to assess health related QOL in children It assesses 4 main areas – physical 
function, social, emotional and social or work domains. This test was used by Kulkarni et al 
for assessment of quality of life of long term survivors of posterior fossa brain tumors, which 
showed that there was no significant decline in quality of life of survivors unless they had 
residual hydrocephalus or were from a poor socio-economic status.(84) 
We have used PedsQl as a tool for studying the quality of life of survivors, as it is a validated 
tool for assessment among brain tumour survivors. 
Justification for this study 
Medulloblastoma is the second most common childhood brain tumour. In this study, we 
looked at the clinical profile and outcome of children with medulloblastoma treated in our 
unit and compared the same with published literature.  
Our study looked at molecular subtypes of medulloblastoma seen in our patient population 
and compared it with clinical profile and outcome. This data was also compared with other 
studies.  
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Quality of life of children with medulloblastoma is compromised due to morbidity from the 
disease itself as well as complications of treatment as mentioned above. In our joint clinic 
with multidisciplinary team, many of these issues were identified and managed on a regular 
basis. During this study, we compiled all the information related to this. QOL assessment 
was done using a standard Peds QL tool from MAPI organization. This tool assesses QOL in 
four domains, namely physical, social, and emotional and work related functioning.  
Permission for using this tool was obtained from the organisation (copy of which is attached 
among the annexures). We hope that this study will help in better understanding and 
management of medulloblastoma, minimising the late sequelae and maximising the quality 
of life of medulloblastoma patients in the future. 
 
 
 
 
 
 
 
 
55 
 
METHODOLOGY 
This study was carried out among the patients who attended the paediatric haematology-
oncology unit of the tertiary care hospital where the primary investigator was doing her 
postgraduate training. The study included patients who had presented to the hematology-
oncology department for treatment of medulloblastoma between the years 2004-2014.  The 
institutional review board approval was sought for and received prior to commencement of 
the study. ( Please see the annexures for the copy of the same). 
There were a total of 149 patients who were diagnosed with medulloblastoma between the 
years 2004-2014 based on biopsy. Of these, 109 were paediatric medulloblastoma and the 
rest were in the adult age group.  Among these 109 paediatric medulloblastoma patients, 73 
sought treatment in paediatric hematology-oncology unit, the rest were lost to follow up to 
RT and oncology, and took surgical treatment alone.  In addition to these 73 patients, 3 
patients whose primary surgery had been performed elsewhere also presented to the 
haematology-oncology department for further management. Hence, a total of 76 patients 
were included in the study for the purposes of clinical profile.  
Among these 76, 50 completed treatment and 10 of them died of recurrence after 
completion of treatment. Of  the remaining 40,  five  were lost to follow up after completion 
of treatment and being in remission for a few years and 2 had recurrence of tumour hence 
was sent home on palliative treatment. Quality of analysis has been done for 33 of the 35 
who were contactable for administering the QOL questionnaire.  
Tumour immunohistochemistry was done for 43 of these 76 patients. Beta catenin was the 
marker that was used, with nuclear positivity categorising the tumour as WNT. Of the 
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remaining tumours which were negative for nuclear beta catenin, those with desmoplastic/ 
medulloblastoma with extensive nodularity histology were categorised as Sonic Hedgehog 
category, whereas the remaining were taken to be non WNT/ non SHH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
40 patients were older than 16 
years at presentation. 
109 patients in the paediatric age group 
underwent surgery for medulloblastoma 
36 patients did not report to 
paediatric oncology 
present to oncology. 
73 patients presented to Pediatric 
oncology for  chemo/ treatment 
3 children who were operated 
elsewhere presented to pediatric 
oncology for further treatment.  
Total of 76 children who were 
treated for medulloblastoma under 
pediatric oncology 
Total number of patients with 
medulloblastoma: 149 
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Clinical profile was derived by retrospective chart analysis. The patients’ treatment records, 
operation notes, radiology data available for the last 10 years, chemotherapy protocols and 
follow up data in OPD charts were utilised for the same. The late effects of therapy, such as 
endocrine dysfunction, cognitive impairment, hearing defects, etc were also looked at.  
Tumour immunohistochemistry were carried out on tissue samples from the tumours which 
were already available in the pathology department from the surgeries which were done 
over the last 10 years. Beta catenin was the marker which was used. In addition to this, 
histology was verified by a senior neuropathologist to confirm the same and to classify the 
ones which were negative for nuclear beta catenin into SHH and non WNT/ non SHH group.  
Further studies were carried out based on the same. 
Quality of life of the survivors was assessed using PedsQL, which is a validated tool for 
assessment of quality of life of brain tumour survivors in the following domains-physical, 
social, emotional and school functioning. Permission was sought from and received from the 
mapi organisation, which owns the copyright for this questionnaire (please see the 
annexures for a copy of the permission letter).  Questionnaires were translated into 
languages which were easy for the patients and the parents to understand, and were 
administered by the principal investigator herself to the patients, either in person or over 
the phone after obtaining informed consent. The patients and parents were also given a 
patient information sheet for clarifying their doubts prior to participation, making it clear 
that participation was absolutely voluntary.  
The results were transcribed onto Microsoft XL sheets after the data was collected. The data 
analysis was done using SPSS version 16.0. 
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RESULTS 
There were 149 patients with medulloblastoma who presented to the neurosurgery 
department of this institute between the years 2004 to 2014. Patients older than 16 years 
(40 patients) were at the time of diagnosis were excluded from this study. 
Of the 109 paediatric patients with medulloblastoma, only 73 came to the paediatric 
haematology-oncology unit for further treatment, the remaining 36 were lost to follow up 
after surgery. Three children with biopsy proven medulloblastoma, who had been operated 
elsewhere, were also included as they took post-operative treatment in our unit. The study 
population therefore includes a total of 76 paediatric medulloblastoma patients who were 
seen in the Department of Paediatric Haemato-oncology unit in this tertiary care centre in 
South India between the years 2004 and 2014 March.  
Clinical profile of patient population  
Among the entire paediatric medulloblastoma population seen in this institute (112 
patients, 109 operated here and 3 operated elsewhere), there were 75 males as against 37 
females, making the male to female ratio 2:1.The gender ratio among the 76 who reported 
to our unit, was 1.8:1 (49 boys and 27 girls) 
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Gender distribution of study population: (n=76)  
Table No. 1: Gender distribution of the study population   
  
Frequency Percent 
 Male 49 65 
Female 27 35 
Total 76 100 
 
There was a male preponderance, with a male: female ratio of 1.8:1. 
Age at presentation (n=76): 
The age at presentation in this study population varied from 1 year to 15 years. The mean 
age at presentation was 8.49 with a standard deviation of +/-3.45. The following table 
represents the different age groups into which our patients belonged.  
Table No. 2: Age distribution of children at diagnosis (n=76) 
Age group Frequency Percentage 
<=3 years 7 9% 
4-7 years 20 26% 
8-10 years 27 36% 
>10 years 22 29% 
 
As depicted in the above table, the study population had only 7 patients in the age group 
that was younger than 3 years. The majority of patients were in the age group 8-10 years, 
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closely followed by those who were more than 10 years. The histogram given below 
represents the age distribution of the study population. 
Figure No.1:  Age at diagnosis for the patient population (in years) 
 
                                  Age at diagnosis (years) 
The histogram depicts how most of the cases were clustered around 8-10 years of age, with 
a few outliers who were less than 3 years and more than 13 years respectively at both ends 
of the age distribution. 
Symptoms at the time of presentation (n=76): 
The various symptoms with which our patients had presented were looked at. The 
predominant symptoms were headache, vomiting, ataxia and visual disturbances.  
The table below gives the details of the symptoms at presentation in our study group. 
 
Frequency 
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Table No. 3: Symptoms of patients with medulloblastoma at the time of presentation 
(n=76) 
Symptom Frequency Percentage 
Headache 65 86% 
Vomiting 60  79% 
Ataxia 44  58% 
Blurring of vision 12  16% 
Increase in head size 3  4% 
Giddiness 3  4% 
Tinnitus 3  4% 
Tremors 1  1% 
Seizures 1  1% 
 
These symptoms are either as a result of raised intracranial tension (headache, vomiting, 
visual disturbances)  due to obstruction to the CSF pathway as a result of the classic midline 
fourth ventricular location of the tumour, or due to the cerebellar involvement due to 
cerebellar location of the tumour or due to pressure effects(ataxia, tremors,  giddiness). In 
our study population, increase in head size was also reported as a presenting symptom in 3 
children who were less than 2 years at the time of presentation. Tinnitus was seen mainly in 
those who had cerebellopontine tumours, as a result of compression of the VIII th cranial 
nerve as a result of the location of the tumour.  
Duration of symptoms prior to presentation (n=76): 
The duration of symptoms prior to presentation to this hospital for further management 
was analysed. The mean duration was 2.69 months +/- 2.21. 
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This data is represented in the histogram given below: 
Figure No.2: Duration of symptoms prior to presentation
 
 
It was seen that 59 patients (78%) presented within 3 months of onset of symptoms. For 
another 13 children (17%), it took between 4-6 months from the time of onset of symptoms 
for a diagnosis to be made whereas 4 out of 76 (5% of the total study population) had a 
diagnosis made only after 6 months of onset of symptoms. 
 
Surgical Treatment and complications  
Emergency pre -op CSF diversion procedures 
Symptoms of raised intracranial tension were one of the most important reasons for seeking 
medical attention. This also meant that some of them had impending herniation, which was 
life-threatening, at the time of presentation itself. These patients were taken up for 
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emergency CSF diversion procedures. The proportion of patients who underwent shunt 
surgery prior to definitive surgery was looked at. 22 of the 76 patients (29 %) had required a 
preliminary shunt surgery, either at this centre or elsewhere. The various shunt procedures 
used were ventriculoperitoneal shunt in 18 of the 22 (82%), extraventricular drainage in 2 
children (9%) and ventriculostomy in two children (9 %)  
The remaining patients could be managed successfully with steroids and other ant-oedema 
measures. 
Post-op CSF diversion procedure (n=76)  
13 patients had ventriculoperitoneal shunts placed for CSF drainage post-operatively. This 
was in addition to the 22 patients who had had shunts pre-operatively, making the total 
number of patients needing CSF diversion procedures in this series 35. This was indicative of 
the fact that in some patients, tumour resection to the safest extent possible might not be 
sufficient for adequate CSF drainage, as shown by Muzumdar et al. These patients did well 
after placement of a CSF shunt, with significant improvement in sensorium.  Over shunting 
of the CSF was seen in 2 of these 35 patients (6%) much later, requiring ligation of the shunt 
tip. 
Surgical resection (n=76) 
Surgical resection of the tumour was classified into subtotal or  gross total based on extent 
of residual tumour. Gross total resection of the tumour indicates a post-op residual tumour 
volume of < 1.5 cm2. Subtotal resection, or residual tumour volume >1.5 cm2 makes the 
patient fall into high risk category. The completeness of surgical resection at primary surgery 
was therefore assessed. It was found that only 37 of the 76 patients (49%) had undergone 
gross resection of the tumour, making the remaining patients high risk disease in view of 
residual tumour.  
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Table No. 4: Completion of surgical resection (n=76) 
 Resection 
Freequency Percentage 
 Gross total  
Subtotal 
37 
39 
49 
51 
   
Total 76 100.0 
  
Residual disease post-operatively (n=76): 
The post-operative scans were analysed to look for residual disease. 48 of the 76 (64 %) had 
radiological evidence of residual disease on the post-operative scans. Of these, 30(39%) 
were more than 1.5 cm2 in size, qualifying them as high risk disease according to the risk 
stratification method advocated by Packer et al.              
  Correlation between surgical excision and residual tumour: The correlation between the 
degree of surgical excision and the volume of residual tumour was considered. The results 
obtained were as below: 
Table No.5: Correlation between surgical excision and residual tumour (n=76)  
 Gross total excision Subtotal  excision  
Residual tumour 
present  
13(35%) 34(87%) 
Residual tumour 
absent 
24(65%) 5(13%) 
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Chi square test was done to look at correlation between the two parameters, and the result 
obtained was 0.23, which was not significant. 
 
Post-operative complications (n=76): 
37 out of the 76 patients (49%) had post-operative complications. The most common post-
operative complication was meningitis in 24%.  However, the most devastating complication 
was posterior fossa syndrome, which was seen in 14 % of the patients post-operatively. 
 CSF leak was treated conservatively with suturing and antibiotics in most cases. Facial palsy, 
which was seen in 11 % of the cases, was transient in all children. Haematomas in the post-
operative bed were monitored closely in 2 of the 5 and were re-absorbed spontaneously, 
whereas the remaining 3 needed re-exploration and evacuation of the haematomas due to 
pressure effects. Hydrocephalus persisting in spite of tumour resection was seen in 6 
patients post-operatively, necessitating CSF diversion procedures post-operatively for the 
same.  
The various post-operative complications encountered were the following: 
Table No. 6:  Post-operative complications 
Serial No: Type of complication Frequency 
1. Meningitis 18(24%) 
2. Posterior fossa syndrome 11(14%) 
3. CSF leak 9(12%) 
4. Facial palsy 8(11%) 
5. Hydrocephalus 6(8%) 
6. Haematomas in post-op bed  5(7%) 
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Figure No.3:  Post-operative complications: 
 
 
Post-operative imaging (n=76): 
Post-operative imaging modalities used were compared among the 76 patients. 93.4 % had 
CT scans, whereas 6.6 % had MRI scans post-operatively.  
Time interval between surgery and post-operative imaging (n=76):  
Post-operative imaging with MRI of the brain  is ideally done before 3 days, as shown by 
Raleigh et al. The reason for this is that after 72 hours, the chances of residual tumour being 
obscured by granulation tissue which will be formed over the post-operative tumour bed is 
much higher, thereby preventing proper visualisation of residual tumour. However, in this 
centre, the current practice is to do a contrast CT in the post-operative period before 
discharge from the neurosurgical side, irrespective of the duration between surgery and 
imaging.  Since contrast will be able to differentiate between blood and residual tumour,  
this is thought of as adequate for imaging residual imaging. Interval between surgery and 
post-operative imaging varies widely among the 76 patients in the study group, from 1 day 
to 32 days after surgery, with a mean duration of 7.05 days +/-5.53. 14 patients of the 
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76(18%) had post-operative imaging done before 72 hours and the remaining 62(82%) who 
had imaging done after 72 hours. 
Figure No. 4: Time interval between surgery and post-operative imaging
 
Staging investigations 
MRI spine for staging (n=58): 
Only 58 of the 76 patients (76%) had been screened using MRI of the spine for evidence of 
leptomeningeal metastases. Of these 58, 23 showed evidence of leptomeningeal metastases 
(40 %), whereas the remaining 35 were normal.  
Like the post-operative screening for residual tumour, MRI spine screening for metastases 
also has guidelines, which state that MRI spine screening should be done either prior to 
surgery, or at least 3-4 weeks after surgery. This is to prevent artefacts due to the presence 
of blood and tissue debris in the CSF circulation in the immediate post-operative period 
which can lead to clumping of the roots, leading to false positive results, or can obscure the 
leptomeningeal metastatic deposits leading to false negative results. 
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In our study population, among the 58 who had MRI screening of the spine done, 7(12%) of  
them had MRI screening prior to surgical intervention, 35(60%) of them had spine screening 
more than 21 days after surgery, and 16(28%) had MRI at less than 21 days after surgery. 
The timing of the imaging was appropriate in 42 (72%) out of 58 patients. 
Figure No. 5:  MRI spine screening for metastatic workup – timing (n= 58) 
 
 
CSF cytology (n=46): 
As part of the metastatic workup, CSF cytology was also done. Fouladi et al have advised 
both MRI spine as well as CSF cytology as part of metastatic workup as their study has 
shown that there are chances of missing leptomeningeal metastases should either one 
investigation be done in isolation. 46 of the 76 patients (61%) in this study population had 
CSF cytology . 39 out of the total 76(51%) had undergone both MRI spine screening as well 
as CSF cytology as part of metastatic workup. 
Among those who underwent CSF cytology, 9 were positive for malignant cells, (20 %), 9 
were unsatisfactory for evaluation (20%) and 28 were negative for malignant cells (60%). 
The results of the cytospin are depicted below:    
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Figure No. 6: Cytospin for evidence of CSF spread of disease- reports 
 
 
Overall, 58/76 (76%) had MRI spine and 46/76 (61%) had CSF cytology done for metastatic 
workup. Only 39/76(51%) had both CSF and MRI spine done.  All children had one or the 
other test done as part of metastatic work up.  It was noted that 6 patients whose spine 
screening had revealed the presence of leptomeningeal metastases had an unsatisfactory 
CSF cytology, whereas 5 children who had been diagnosed with leptomeningeal metastases 
based on MRI spine screening had cytology which was negative for malignancy. Similarly, 2 
children whose cytology were positive for malignancy had imaging of the spine which was 
negative for metastatic spread of the disease.  CSF cytospin and MRI of the spine were both 
positive for metastases in 6 children. If CSF cytospin alone had been performed on all the 
children in this cohort, 11 children with metastases would not have been detected, whereas 
MRI spine screening alone would have been insufficient for diagnosis of metastases in one 
child. This shows how combined screening with both CSF cytology as well as MRI is still 
better than cytology alone or MRI alone. Based on cytology and/or MRI spine screening 
27/76 (36%) had metastatic disease.  
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Surgical procedures for localised versus metastatic disease( n=76) 
Surgical procedures for localised disease and metastatic disease were compared. The results 
obtained were as follows: 
Table No.8: Comparison of surgical resection patterns in metastatic and non metastatic 
disease 
 Metastatic disease Non metastatic disease 
Gross total resection 13(48%) 35(71%) 
Subtotal resection 14(52%) 14(29%) 
48% of those with metastatic disease had undergone gross total resection of the tumour, 
whereas 71% of those with non metastatic disease had undergone gross total resection. 
Student t test was applied to the above data to look for significance, however the p value 
obtained was 0.10172, which was not significant. 
Residual disease in metastatic disease versus localised disease: (n=76) 
Residual disease among those with metastatic disease and those with localised disease was 
compared. The results are shown below: 
Table No.9: Comparison of residual disease in metastatic and localised disease 
 Metastatic disease Localised disease 
Residual disease present 15(55%) 14(29%) 
Residual disease absent 12(45%) 35(71%) 
This shows how 55% of those with metastatic disease had residual disease, whereas only 
29% of those with non metastatic disease had residual disease. 
Age of children at presentation versus metastatic disease(n=76) 
The age of children at the time of presentation(<=3 years or more than 3 years) was 
compared with the metastatic status of the disease. The results obtained are given below: 
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Table No.10:  Metastatic versus localised disease in different age groups  
 Metastases present No metastases 
Age <= 3 years 2(29%) 5(71%) 
Age more than 3 years 25(36%) 44(64%) 
 Only 29 % of those aged less than 3 years at the time of diagnosis had metastatic disease, 
whereas 36 % of those older than 3 years at the time of diagnosis had metastatic disease. 
Student t-test was applied to the above data to look for correlation, however the p value 
was 0.24, indicating no statistical significance. 
Duration of symptoms versus metastatic stage of disease ( n=76) 
The duration of symptoms prior to presentatione was analysed, in comparison with the 
metastatic state of the disease. The data obtained was as below: 
Table No.11:  Duration of symptoms versus stage of disease 
 Metastatic disease  Localised  disease  
Duration<= 3 months 19(33%) 39(66%) 
Duration > 3 months 8(45%) 10(55%) 
It was seen that 33 % of those with duration of symptoms less than 3 months at the time of 
presentation had metastatic disease, whereas 45% of those with duration of symptoms 
more than 3 months at the time of presentation had metastatic disease. T- test was applied 
to the above data to look for significance, however the p value was 0.112, indicating no 
significance. 
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Histology of the tumours (n=57): 
Of the 76 patients in the study group, detailed histology was available only in 57 cases.  In 
the remaining 19 case the biopsy was reported as  medulloblatoma WHO grade IV. 
 Table No.12: Histology of the tumours 
Histology Frequency 
Classic 21(37%) 
Desmoplastic 19(33%) 
Medulloblastoma with extensive nodularity 9(16%) 
Large cell anaplastic  5(9%) 
Anaplastic 2(4%) 
Medullomyoblastoma 1(2%) 
 
Figure No. 7: Histology of the tumours
 
Majority of the tumours showed a classic histology, with desmoplastic forming the next 
most common category.  
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Histology and surgical excision: 
The completeness of resection was compared with the histology of the tumours. Since it has 
been shown that classic and medullomyoblastoma have similar outcomes, as do 
desmoplastic and MBEN( good outcome) and anaplstic and LCA( poor outcome), these were 
combined to form three groups- group 1 consisted of classic histology as well as 
medullomyoblastoma, group 2 consisted of desmoplastic medulloblastoma and 
medulloblastoma with extensive nodularity, and group 3 consisted of large cell anaplastic 
and anaplastic variant of medulloblastoma.  It was found that majority of those belonging to 
classic/ medullomyoblastoma group (17 out of 22, 7%), had gross total resection of the 
tumour. In the group comprised of desmoplastic medulloblastoma and medulloblastoma 
with extensive nodularity, 15 out of 28(54%) had undergone gross total resection. In the last 
group of large cell anaplastic and anaplastic variants, only 1 out of 7(14%) could be resected 
completely. T-test was applied to this data to look for significance, however, the p value was 
0.47, which was not significant. The results obtained when comparing the frequency of 
gross total resection and subtotal resection of tumours in relation to these groups, is 
depicted below.  
Table No.13: Frequency of gross total and subtotal surgical resections among the different 
histological variants 
Histology Gross total 
resection 
Subtotal 
resection 
Total frequency 
Classic 
+medullomyoblastoma 
17 5 22 
Desmoplastic/ MBEN 15 13 28 
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Large cell anaplastic/ 
anaplastic 
1 6 7 
Total 33 24 57 
 
Figure No. 8: Histological variants and completeness of surgical resection: 
 
Histology in comparison with presence of residual tumour: 
The histology of the tumour was compared with presence of residual tumour in the 
post-operative scans. 17 out of the 22(77%) tumours exhibiting 
classic/medullomyoblastoma histology showed residual tumours in the post-operative 
scans.  13 out of 15 tumours (86%) of the tumours in the desmoplastic/ MBEN group and 
6 out of the 7 (86%) tumours in the LCA/ anaplastic group showed evidence of residual 
tumours on the post-operative scans. T- test was applied to this data, to look for 
significance, the result of which was 0.6081, which was not significant.  The results of 
the same are depicted below:  
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Figure No. 9: Histological types and presence of residual tumour 
 
 Risk stratification 
Risk stratification was done based on (i) age at presentation (ii) extent of surgery (iii) 
metastatic vs localised disease based on CSF & MRI spine  
Histology and stage of disease  
The histological types and the presence of metastases were assessed by comparing 
histology with CSF cytospin results and MRI spine results.  
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Table No. 14: CSF cytospin results and comparison with histology 
Histology CSF cytospin 
positive 
CSF cytospin 
negative 
CSF cytospin 
unsatisfactory 
Cytospin not 
done 
Classic + 
medullomyoblastoma(n=22) 
1(5%) 8(36%) 4(18%) 9(41%) 
Desmoplastic +MBEN(n=28) 2(7%) 12(43%) 3(11%) 11(39%) 
Anaplastic +LCA(n=7) 2 2 0 3 
Only one of the 22(5%) in the classic histology group had evidence of metastases 
whereas 2 of 28(7%) and 2 out of 7(29%)  of those in desmoplastic and anaplastic group 
had evidence of metastatic disease. 
  
Table No.15: MRI spine screening results with histology: 
Histology MRI spine s/o 
metastases 
MRI spine negative 
for metastases 
MRI spine not 
done 
Classic + 
medullomyoblastoma 
6(27%) 10(46%) 6(27%) 
Desmoplastic + MBEN 10(36%) 14(50%) 4(14%) 
Anaplastic + LCA 1(14%) 5(72%) 1(14%) 
39 out of the total 76(51%) had undergone both MRI spine screening as well as CSF cytology 
as part of metastatic workup. Both were positive in 6 , both were negative in 20, whereas 
MRI spine was positive in 11 with negative cytology, and CSF was positive in one with 
negative MRI.  
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Figure No.10: MRI spine for evaluation of drop metastasis among various histological 
types.  
 
 
Risk stratification of the tumours (n=76):  
Based on the risk stratification methods proposed by Packer et al, the entire population 
was divided into standard risk and high risk groups. Those whose age at diagnosis was 
less than 3 years, had metastases at the time of diagnoses or had residual tumour 
volume of >1.5 cm2 were treated as high risk disease, whereas those whose age was 
more than 3 years at the time of diagnosis, had non-metastatic disease at the time of 
presentation and had residual tumour volume of <1.5 cm2 at the end of surgery were 
classified as standard risk disease. 
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Table No.16: Risk stratification of the tumours 
Factor for stratification Standard risk High risk 
Age at presentation(<=3 yrs vs >3 
yrs) (n=76) 
69 7 
Metastatic disease (present or not) 
(n=76) 
49 27 
Residual disease(present or not)  
N(n=76) 
46 30 
 
 According to this, 43 patients (57%) fell in the high risk category whereas the remaining 
33(43%) were in the standard risk category. 
 According to the histological groups, 12 of the 22(55%) of the classic/ 
medullomyoblastoma group were high risk disease. 16 of the 28(57%) in the 
desmoplastic/ MBEN group were high risk and 6 out of 7(86%) in the anaplastic/LCA 
group were from the high risk disease category. 
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Figure No. 11: Risk stratification among the histological types. 
 
Post operative treatment ( Radiotherapy and chemotherapy)  
Radiotherapy(n=57) 
Of the 76 patients who had reported to the paediatric haematology-oncology unit after 
surgery, 71 reported to the radiotherapy department for treatment. Out of these, 7 were 
not eligible for radiotherapy as they were less than 3 years of age at the time of diagnosis. 
Of the remaining 64, 57(89%) completed their radiotherapy here. 2 completed radiotherapy 
elsewhere before coming for further chemotherapy here at a later date. Hence, of the 76 
who had presented, only ten had defaulted therapy before commencement of radiotherapy.  
Time interval between surgery and radiotherapy (n=59): 
 According to the COG ( Children’s Oncology Group) guidelines, the optimum gap between 
surgical excision and radiotherapy is 2 weeks- 4 weeks, i.e, radiotherapy can commence 
once 2 weeks of post-operative period is over and should ideally commence before 4 weeks 
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are over. The SIOP guidelines also recommend commencement of radiotherapy within 4-6 
weeks. The mean gap between surgery and commencement of radiotherapy among the 59 
children who took radiotherapy either in this institute or elsewhere was looked at, and was 
found to be 33.36 days+/-18. The least gap was 11 days, and the maximum gap was 96 days. 
In the study population, 4(7%) commenced RT before 14 post-operative days were 
completed, 42(71%) commenced RT between 15-42 days post-operatively, whereas 13 
(22%) commenced RT after more than 43 days post-operatively. These delays occurred as a 
result of post-operative complications such as meningitis (8 of the 13 cases with delay in 
commencement of RT), CSF leak (3 out of 13) and stormy post-operative course with 
haematoma in tumour beds (2 out of 13), etc. The timing of commencement of 
radiotherapy was appropriate in 71 % of the total study population.  
Figure No.12: Timing of commencement of radiotherapy: 
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Figure No.13: Time interval between surgery and radiotherapy:  
 
Complications of radiotherapy (n=57): 
Of those who underwent radiotherapy here, 50% had radiotherapy induced complications. 
These complications were significant enough to cause a delay in completion of radiotherapy 
among 21(37 %). The mean delay was 13 days, and the longest, 25 days. The various 
complications encountered by those who underwent radiotherapy are listed below: 
Table No:17- Complications of radiotherapy: 
Complication Frequency 
Neutropenia 18(32%) 
Radiation induced skin reactions 8(14%) 
Hypertension 2(4%) 
Mucositis 2(4%) 
Herpes zoster reactivation 2(4%) 
Optic atrophy 1(2%) 
Stent infection 1(2%) 
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Steroid induced gastritis 1(2%) 
Pancreatitis 2(4%) 
Seizure 1(2%) 
Vertigo 1(2%) 
 
The dose of radiotherapy given was looked at. The standard recommendation according to 
the SIOP guidelines were 36 Gy of radiation to the craniospinal region with a posterior fossa 
boost of 18 Gy.  44 of the 59(75%) were able to complete 36 Gy of RT to the craniospinal 
region with a posterior fossa boost of 18 Gy. 3 patients (5%) with high risk disease received 
additional RT when compared to the rest. 4 patients (7%) got less than 18 Gy boost to the 
posterior fossa as their radiotherapy schedule had been prolonged by more than 2 weeks. 
Chemotherapy (n=60): 
Of the 76 patients who had presented to paediatric haemato-oncology department, 60 
(79%) took chemotherapy at this centre.   
Time interval between RT and chemotherapy (n=60): 
The Packer regimen for chemotherapy advocated 6 weeks as the ideal interval between 
completion of radiotherapy and commencement of chemotherapy. Our institute follows the 
Packer regimen for children more than 3 years of age at the time of diagnosis, with 8 cycles 
of chemotherapy with lomustin, cisplatin and weekly vincristine starting 6 weeks from the 
time of completion of radiotherapy. 56 patients were treated with Packer regimen. 4 of this 
56 (7%) had commenced chemotherapy before 42 days, 31(54%) commenced 
chemotherapy within an interval of 43-56 days and 21(38%) started their chemotherapy 
only after more than 57 days after completion of chemotherapy.  The reasons for delay in 
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chemotherapy was patients presenting late (16 cases), prolonged neutropenia after 
radiotherapy (2), recurrent pancreatitis (1) and meningitis (1)., 1 had meningitis and 1 had 
completed radiotherapy elsewhere before presenting here with extraneural metastases for 
treatment. Timing of commencement of chemotherapy was appropriate in 54 % of the 56 
patients treated with the Packer regimen. The mean interval between RT and chemotherapy 
was looked at, and was found to be 56.08 days +/-19.19. The minimum interval between RT 
and chemotherapy was 21 days. There was a single patient who commenced his 
chemotherapy 600 days after his radiotherapy was completed. This patient had undergone 
his surgery and radiotherapy elsewhere, and had presented 1 year and 9 months after 
completion of radiotherapy with extraneural metastases. 
 4 of these 60 had been treated with baby brain protocol as they were less than 3 years of 
age at the time of diagnosis. The baby brain protocol states that idea time of 
commencement of post-operative chemotherapy was between 2-3 weeks after surgical 
resection. Among the 4 children who were treated with baby brain protocol, chemotherapy 
was started within 21 days for 3 children, whereas one child started after 64 days as he had 
completed his surgical excision elsewhere and presented here after 2 months for further 
management. Hence timing of commencement of chemotherapy was appropriate in 75% of 
these patients (3 out of 4 patients). Mean interval between surgery and chemotherapy was 
25.4 days +/-20. 
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Figure No. 14: Interval between radiotherapy completion and   commencement of 
chemotherapy:  
 
 
Figure No. 15: Timing of commencement of chemotherapy 
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Details of chemotherapy (n=60): 
All patients who were more than 3 years at the time of diagnosis were planned for 
chemotherapy based on Packer regimen, with 8 cycles of chemotherapy being planned. The 
mean number of chemotherapy cycles received by each patient was 6.63, with a standard 
deviation of 2.2. The median number of cycles of chemotherapy received was 8. The least 
number of cycles received was 1, where the patient discontinued chemotherapy after the 
first cycle and was thereafter lost to follow up. The maximum cycles of chemotherapy 
received were 8 cycles. The ones who were treated with baby brain protocols were planned 
for 7 cycles according to SFOP regimen. 
The number of chemotherapy cycles received by the children treated under this institute 
are depicted below: 
Table No. 18: Number of chemotherapy cycles taken: 
Number of cycles of 
chemotherapy taken here 
Frequency Percentage 
8 36   60 
7 5 8 
6 6 10 
5 2 3 
4 3 5 
3 0 0 
2 3 5 
1 5 8 
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Of the 56 patients treated with Packer regimen chemotherapy, 36 had completed all 8 
cycles of chemotherapy. Of the remaining 20, treatment was stopped prematurely for 9 due 
to toxicities- profound hearing loss, neurotoxicity or prolonged cytopenia. 2 children died 
while on chemotherapy, one due to septic shock and one due to unknown causes (she was 
brought gasping to casualty after PCV cycle 6, and could not be resuscitated). 47 out of the 
60(78%) had completed their chemotherapy and 11 out of 60(18%) had defaulted 
treatment, whereas two (3%) had died while on chemotherapy.  
Of the four who were on baby brain protocol, 2 had completed 7 cycles of chemotherapy 
with carboplatin, procarbazine, cisplatin, etoposide, cyclophosphamide and  vincristine as 
per protocol, however 2 of them had only 6 and 2 cycles respectively before having disease 
progression and discontinuing treatment. 
Treatment modifications (n=60) 
24 of the 60 who had chemotherapy had changes in their drug regimen. This change was 
due to the following reasons- ototoxicity as a result of cisplatin, cytotoxicity as a result of 
lomustin and vincristine, neuropathy as a result of vincristine or nephrotoxicity due to 
cisplatin. If cytopenia was significant, lomustin was omitted, and carboplatin was 
substituted for those with significant hearing loss/ renal tubular issues.  Vincristine dose was 
decreased for cytopenia and omitted if neuropathy was significant. The reason for 
modifications in treatment regimen is documented below: 
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Figure No. 16: Reasons  for change in chemotherapy regimen 
 
 
 
The mean duration of cytopenia associated with chemotherapy was 9.28+/-19.37 after PCV( 
week 1). 4 patients had their chemotherapy protocol truncated as a result of prolonged 
cytopenia, whereas a total of 9 patients had changes in their protocol as a result of 
cytopenia. The changes in the protocol were as mentioned above.Musial Bright et al in their 
studies on susbstitution of carboplatin for cisplatin in order to decrease the ototoxicity of 
the regimen found that the efficacy of the drug was as good as that of cisplatin with 
significant reduction in the hearing loss involved.(85) 
 
Outcome  
The table given below depicts the treatment received by the children. 
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Table No.19: Treatment received by the cohort: 
*4 children  were too young to receive RT  
The above table represents the treatment received by the children 
 
Table No. 20: Outcome of children at the time of analysis of this study.  
Treatment outcome Frequency Percentage 
Completed treatment, in 
complete remission 
32 42 
Completed treatment 
Relapsed, on palliative 
treatment 
2 3 
Completed treatment, lost 
to follow up 
4 5 
Died ( disease/other 
complications)  
19 25 
 
Category 
Frequency Percentage 
Total number in the study 76 100 
Surgery alone 16 21 
Surgery + Radiotherapy 0 - 
Surgery + Radiotherapy 
+Chemotherapy 
60* 79 
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Abandoned treatment 5 7 
Refused treatment 14 18 
  
We have defined lost to follow up as patients who completed treatment, achieved disease 
remission and subsequently who failed to review for more than 36 months and were not 
contactable. Those who had started treatment at this institute,  but defaulted treatment 
prior to completion of all the planned treatment as per protocol, irrespective of 
complications, were considered to have abandoned treatment. 
In our patient population, we had 4 who were lost to follow up. Among the 32 with disease 
remission and on follow up, 17 have been in disease remission for 2 years or less, whereas 8 
have been in CR for between 2 to 5 years and 7 have been in disease remission for more 
than 5 years, and can therefore be considered to have survived this disease.  
Figure No. 17:- Follow up details: 
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Figure No.18: Cause of death  
 
Data of 19 children who died were available for analysis.  14/19 (74%) had high risk 
disease. The mortality rate among those with standard risk disease was 15% (5/33) and 
those with high risk disease it was 33 %( 14/43).    
 
Table No. 21: Treatment outcomes in comparison with different risk factors (n=76)  
 
 
 
 
    Complete 
remission Recurrence Death 
Treatment 
abandoned 
<= 3 years 
 
4(57%) 0 2(29%) 1(14%) 
>3 years 
 
32(46%) 2(3%) 17(25%) 17(25%) 
Gross total 
resection 
 
27(68%) 0 8(17%) 13(27%) 
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Subtotal resection 
 
9(32%) 2(7%) 12(43%) 5(18%) 
Metastases present 
 
12(37%) 2(7%) 9(33%) 4(15%) 
Metastases absent 
 
24(49%) 0(0%) 11(22%) 14(29%) 
 
 
High risk disease versus standard risk disease:  
Using age less than or equal to  3 years, gross residual tumour and metastatic disease as 
indicators of high risk disease as proposed by Packer, we found that our study population 
had 33 patients in the standard risk category and 43 in the high risk category by at least one 
of the above criteria. The outcomes among these two groups were as follows: 
Table No. 22:  Outcome among standard risk group compared with that of high risk group 
Outcome Disease 
remission 
Recurrence Death Treatment 
abandoned 
Standard risk 
(n=33) 
18 0 5 10 
High risk 
(n=43) 
18 2 14 9 
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Figure No. 19: Comparison of outcome among high risk group versus standard risk group 
 
Comparison of outcome of the various histological types (n=52): 
The outcome of the various histological types were combined into similar histological types 
and analysed, among the ones whose outcome was known. There were no statistically 
significant difference between the different types. 
            Table No. 23: Outcome of various histological subtypes  
Histological subtypes Total 
number 
Disease 
remission 
Death Relapse, 
on 
palliative 
chemo 
Classic+ Medullomyoblastoma 17 14 3 0 
Desmoplastic +MBEN 19 8 9 2 
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Anaplastic + LCA 6 3 2 1 
 
 
Figure No. 20: Outcome of various histological types: 
 
 
Outcome of those who had recurrence of tumour (n=19): 
Of the 19 who had disease recurrence, only two are still alive, on palliative chemotherapy 
whereas the rest had expired. The mean duration between surgery and recurrence was 
considered, since a few hadn’t completed their treatment (radiotherapy and 
chemotherapy). The mean duration in months between primary surgery and recurrence was 
22.39, with a standard deviation of 16.03.  The median interval was 17.5 months. The 
minimum interval was 4 months, and the maximum duration was 67 months after surgery. 
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Figure No. 21: Time interval between initial surgery and recurrence:
 
 
Of the 19 with disease recurrence, 16 (84%) were high risk and 3(16%) were low risk 
according to the risk stratification methods described by Packer et al.  Gross total resection 
of the tumour had been done with a residual tumour volume less than 1.5 cm2 on post-
operative imaging, in 6 of the 19(32%), whereas 13 out of 19 (68%) had undergone subtotal 
resection, with a residual tumour volume of more than 1.5 cm2.  Metastatic disease was 
present in 10 out of 19(53%). The age at diagnosis was less than 3 years in 2 of the 19 
children (12%).  
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Comparison of different age groups at diagnosis with the prognosis (n=76): 
There were 7 children who were aged 3 years or less at the time of diagnosis. Of these, only 
6 commenced chemotherapy. 4 did well, and are in clinical remission with disease-free 
intervals of 8 years, 5 years, 4 years and 3 years respectively. One was lost to follow up 
before commencing chemotherapy. The other two, who started chemotherapy, had 
progression of disease while on chemotherapy, and discontinued treatment. Subsequently, 
it has been informed that these two expired of disease.  
69 of the 76 patients (91%) were aged more than 3 years at the time of presentation. Of 
these, 32 had disease remission (46%), 2(3%) have disease recurrence and are currently on 
palliative chemotherapy, 18(26 %) have been lost to follow up and 17(25%) have expired. 
Table No. 24: The outcome for those less than 3 years compared with those older than 3 years at the 
time of diagnosis  
Age at diagnosis(in 
years) 
Disease remission Recurrence Death Treatment 
abandoned 
<=3(n=7) 4 0 2 1 
>3(n=69) 32 2 17 18 
 
Since age less than 3 years was considered to be high risk according to the risk stratification 
proposed by Packer et al, the outcome of those who were less than 3 years of age at the 
time of diagnosis was compared with those who were older than 3 years at the time of 
diagnosis of medulloblastoma. The data given above was analysed using Pearson chi-square 
test. The p value for this data was 0.98, which shows that there was no statistically 
significant difference between the two groups.  
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Duration of symptoms at the time of presentation vs outcome 
The final outcome was also compared among those with varying duration of symptoms 
at the time of presentation, namely more than 3 months and less than 3 months at the 
time of diagnosis. Among the 46 people who had presented before 3 months of 
symptoms, 35 are in disease remission and 11 had died. Among 14 patients who 
presented only after more than 3 months of symptoms, 6 were cured and 8 had died. 
Fisher’s exact test was used for analysis of the above data, and a p value of 0.054 was 
obtained, which showed that there was no statistically significant difference between 
the two groups in terms of outcome. 
 
Figure  No. 22: Comparison of outcome of those with varying duration of symptoms at 
the time of diagnosis    
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Comparison between the outcome of those who had  gross total  excision of the tumour 
with those who had subtotal excision of tumour: 
The outcome of those who had subtotal excision of tumour was compared with those who 
underwent gross resection of the tumour. Among those with gross total resection, 27 were 
in complete remission, 8 had died and 13 had abandoned treatment. Among those who had 
undergone subtotal resection, 9 had achieved complete remission, 2 had had recurrence, 12 
had died and 5 had abandoned treatment. Pearson’s chi square was applied to this data to 
look for correlation, however the p value obtained was 0.238, hence this was not significant.  
 
Figure No. 23: Comparison of outcome among those with subtotal resection of the tumour 
vs those with gross total resection of the tumour: 
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Late effects of treatment in children with medulloblastoma  
48 children were followed up for delayed complications of treatment in this group. This 
assessment was done at the time of completion of treatment, however was updated at each 
review. The common complications seen were peripubertal issues, hearing loss, permanent 
hair loss, endocrine issues and psychosocial issues. Delayed puberty was seen in 6, with 
premature ovarian failure in 2. Hearing loss, significant enough to affect daily life, i.e, 
moderate to profound hearing loss, was seen in  12 patients, whereas 30 of the 47 had 
some degree of hearing loss. Permanent hair loss was seen in 22 children who had 
completed treatment. The various endocrine issues have described in detail below.  
Depression, excessive aggression, attention-deficit hyperactivity syndrome and other 
behavioural issues were seen in a few children, for which they have been assessed by child 
psychiatrists and developmental paediatricians, and are on follow up for the same. None of 
the children had expressed suicidal ideation in the follow up cohort.   
Table No.25: Late effects of treatment  
Complication Frequency Percentage 
Hearing loss 30 62% 
Endocrine issues 26 55% 
Permanent hair loss 22 46% 
Peripubertal issues 8 17% 
 
The frequency of the delayed effects of treatment are shown below: 
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Figure No. 24: Delayed complications of treatment:
 
Of the 30 who had hearing loss, 12 have moderate to severe sensorineural hearing loss, and 
have been advised hearing aids for the same.  
Endocrine dysfunction(n=48)   
It is well known that the survivors of medulloblastoma have varying degrees of endocrine 
dysfunction as a result of radiation exposure to the head and neck region.  These late-
effects are some of the most frequently studied late effects seen in survivors of childhood 
malignancies, especially central nervous system malignancies.  
We looked at the various endocrine issues among our study population and found that 26 of 
the 48 had endocrine sequelae. Hypothyroidism was seen in 19 children, who are on regular 
thyroxine supplementation. Compliance has been good in most cases, and the parents 
recognise the need for therapy. Hypocortisolism was seen in 2 children, who are on 
hydrocortisone supplements for the same.  Though short stature was seen in many of the 
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survivors, only 4 were identified to have GH deficiency.  Premature ovarian failure was seen 
in 2 of the survivors, and 6 children had had delayed onset of puberty. 
The various problems and their frequency are listed below 
Figure No.25: Endocrine sequelae among survivors 
 
 
Molecular subgroups of medulloblastoma (n=43) 
With immunohistochemical marker beta catenin and histology, the tumours were 
subdivided into various molecular subgroups in 43/76 cases. The tumours were divided into 
the following subgroups- WNT, SHH and non WNT/non SHH. Beta catenin was used as a 
immunohistochemical marker for subtyping the tumour.  Nuclear beta catenin positive 
cases were grouped as WNT category. Tumours that were beta catenin negative and had 
either desmoplastic or extensive nodularity on histology constituted the sonic hedgehog 
(SHH) subgroup. The ones that were negative for nuclear beta catenin, and had histology 
other than desmoplastic/ MBEN were taken as group 3 and group 4, or non WNT/ non SHH 
subtype. 
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Table No.26: Frequency of the various molecular subtypes (n=43)  
Molecular subgroup Frequency 
WNT 26 
SHH 13 
Non WNT/non  SHH 4 
 
Figure No. 26: Distribution of the various molecular subtypes among the patients
 
Comparison of tumour immunohistochemistry with histology(N=43): 
The tumour immunohistochemistry markers were compared with histology of the tumours. 
19 of the 26 WNT tumours were classic in histology, with another 2 each showing 
desmoplastic and large cell anaplastic histology. One patient each in WNT subgroup 
exhibited medulloblastoma with extensive nodularity, medullomyoblastoma and anaplastic 
histology. In the SHH group, 69% had desmoplastic histology, whereas 31 % was 
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medulloblastoma with extensive nodularity. Non WNT/ non SHH group had 50 % classic 
histology and 50 % large cell anaplastic histology. 
 
Table No.27: comparison of tumour IHC with histology    
Tumour IHC - comparison with Histology 
   
HIstology  
Total 
   
Classic Desmoplastic MBEN Anaplastic LCA Medullomyoblastoma 
   19 2 1 2 1 1 26 
WNT        
                    SHH 0 9 4 0 0 0 13 
        
Non WNT/ 
Non SHH 
 2 0 0 2 0 0 4 
 50 0 0 50 0 0 100 
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Figure No. 27: Different histological types within each subtype:
 
Molecular subgroups versus risk stratification: 
Molecular subgroups have been known to have correlation with outcome and to be of value 
in prognostication of disease. On comparing molecular subgroups with the standard risk 
stratication as proposed by Packer et al, the following data was obtained. 
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Table No. 28: Molecular subgroups versus risk stratification: 
Molecular subgroup WNT(n=26) SHH(n=13) Non WNT/non 
SHHH(n=4) 
Standard risk disease 15(58%) 6(46%) 1(25%) 
High risk disease 11(42%) 7(54%) 3(75%) 
 
58% of WNT subgroup belonged to standard risk group, whereas only 46% and 25 % each of 
SHH and non WNT/non SHH group belonged to the standard risk group. On analysing the 
correlation between risk stratification and molecular subgroups, it was found that there was 
there was result tended towards significance(p value =0.056) 
 
 
Molecular subgroups versus outcome: 
Tumour immunohistochemistry was used to compare the outcome between WNT, SHH and 
non WNT/non SHH. However, since the numbers in the third group was very small for 
comparison, the WNT subgroup was also compared with the non WNT subgroup which 
comprised of SHH subgroup as well as group 3 and group 4. Of the 43 cases with available 
immunohistochemistry, 26 belonged to WNT subgroup, 13 belonged to SHH and 4 to non 
SHH/ non WNT group. Among the 26 children in the WNT subgroup, 5 were lost to follow-
up. In the SHH 5 had been lost to follow up. For the purpose of analysis, we compared WNT 
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group with non-WNT and it was found that WNT group had significantly better outcome.(p= 
0.016).  
Table No. 29: Outcome measures among the three subgroups: 
Subgroup Disease 
remission 
Death Recurrence Treatment 
abandoned 
WNT (26) 18 3 0 5 
SHH (13) 3 4 1 5 
Non WNT/ non 
SHH (4) 
2 2 0 0 
 
Since the numbers in SHH and non WNt/non SHH were very small for meaningful 
comparison, we combined the SHH and non WNT/non SHH group into one group, the non 
WNT subgroup. Further comparisons were carried out between the WNT subgroup and the 
non WNT subgroup. 
Table No.30: Outcome measures among the WNT group and the non WNT group: 
Subgroup Disease 
remission 
Recurrence Death Treatment 
abandoned 
WNT(n=26) 18(69%) 0 3(12%) 5(19%) 
Non WNT(n=17) 5(29%) 1(6%) 6(35%) 5(29%) 
  
The above data shows that 69% of the WNT subgroup had achieved disease remission, 
whereas only 29% had achieved disease remission in the non WNT group. Only 12 % of 
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those in the WNT subgroup had died, whereas 35 % of those in the non WNT group had 
expired. It is quite clear from the above that the WNT group had better outcomes when 
compared with the non WNT group. When analyzed with anova multivariate analysis, the p 
value for this correlation analysis was 0.016, which means that this difference is statistically 
significant.   
Tumour location with respect to molecular subtypes 
The location of tumours and the correlation with immunohistochemistry was analysed as 
previous studies by Perrault et al had shown correlation between these.  According to the 
study by Perreault, 75 % of the WNT tumours occurred along the cerebellopontine angle. 
SHH tumours were usually cerebellar, and group 3 and group 4 were predominantly midline, 
arising from the fourth ventricle. We analysed our data to see whether similar trends were 
present in our data as well. Tumours were classified by location into midline tumours, 
cerebellopontine tumours and cerebellar tumours. Of the 43 tumours which had 
immunohistochemistry available, 35 (81%) were midline in location, with cerebellopontine 
tumours and cerebellar tumours accounting for 3 (7%) and 5 (12%) each. When we 
compared location of tumour with various molecular subtypes, we did not find any 
significant correlation,(p=0.83)  as 81 % of the tumours in our group were located in the 
midline. On analysing the location of the tumours with respect to the molecular subgroups, 
no correlation could be found. The p value for this analysis was 0.83. 
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Table No.31: Comparison of tumour location with molecular subtypes  
Tumour Location WNT SHH Non WNT/non SHH 
Midline 22 10 3 
Cerebellopontine 1 1 1 
Cerebellar 3 2 0 
 
QUALITY OF LIFE OF SURVIVORS 
Quality of life of 33 of the children who are under follow up we assessed- 31 in remission, 2 
on palliative treatment for recurrence. The assessment was carried out using  PedsQL, a 
validated tool for assessment of quality of life of brain tumour survivors. The questionnaire 
assesses the quality of life in the following domains-physical, emotional, social and school 
functioning. Of these, the average of emotional, social and school functioning results is 
taken as the psychosocial QOL score. The total scores are the average of all domains taken 
into consideration. The median scores in the various domains and the total scores are listed 
below(all scores are on 100, with scaling from 0-100, with 0 being the worst and 100 being 
the maximum score indicating the best function). The module has different ones for 
different age groups and parent answered questionnaires as well as self answered modules. 
These were administered according to age and on whether child answered or the parents 
answered for them.  
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Table No.32: QOL scores among survivors who had completed treatment for 
medulloblastoma 
Dimension Minimum Maximum Mean Standard 
deviation 
QOL-physical 6.25 96.80 67.23 17.79 
QOL-emotional 40.00 90.00 67.00 12.95 
QOL-social 50.00 100.00 71.61 12.47 
QOL-school 
functioning 
20.00 95.00 62.58 15.43 
QOL-
psychosocial 
36.66 90.00 67.25 11.51 
QOL-total 33.69 92.39 67.37 12.83 
 
Comparison of quality of life of disease-free survivors with that of those with disease 
recurrence:  
While comparing QOL of those in CR with that of those with recurrence, there was an 
obvious difference with those in CR having a better QOL.  
Table No.33: - Comparison of QOL scores of those with recurrence with those with disease 
remission: 
Domain QOL-
physical 
QOL-
emotional 
QOL-
social 
QOL-
school 
QOL-
psychosocial 
QOL-total 
Disease 
remission(n=31) 
69.97+/- 
16.11 
70.17+/- 
11.26 
73.39+/- 
11.55 
66.25+/- 
10.76 
69.81+/- 
8.52 
70.01+/- 
10.10 
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Recurrence(n=2) 48.43+/-
6.62 
50.00+/- 
7.67 
57.50+/- 
10.60 
32.50+/- 
3.53 
46.60+/- 
7.07 
47.28+/- 
6.91 
P value  0.04 0.043 0.076 0.018 0.02 0.03 
 
Though the p values seem significant, since the numbers in the recurrence group is very 
small when compared with those in the disease remission arm, this data might not be valid. 
 
 
Comparison of QOL of survivors who had tumours with WNT expression with those whose 
tumours did not have WNT expression:  
 Since there was a statistically significant survivor advantage for those in the WNT subgroup 
when compared with the non WNT subgroups in published literature, we compared  QOL in 
WNT with the  non WNT group.  Of the 33 who had quality of life analysis, only 18 had been 
subdivided into WNT/ non WNT subgroups based on immunohistochemistry and histology. 
Analysis of the same did not reveal any significant difference.  
Table No. 34: Comparison of QOL of survivors with WNT expression against those with no 
WNT expression  
Domain QOL-
physical 
QOL-
emotional 
QOL-
social 
QOL-
school 
QOL-
psychosocial 
QOL-total 
WNT(n=14) 68.29+/-
17.4 
67.50+/-
13.8 
73.21+/- 
13.6 
63.21+/-
17.6 
67.96+/-13.1 68.21+/- 
14.3 
Non 74.21+/- 75.00+/- 67.50+/- 71.25+/- 70.41 +/- 72.28+/- 
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WNT(n=4) 9.3 9.1 6.4 11.1  6.4 6.9 
P value 0.522 0.332 0.415 0.307 0.789 0.523 
 
This might be a reflection on the fact that all children, irrespective of whether high risk or 
standard risk, get standard treatment according to current protocols with no escalation of 
treatment for high risk patients. Hence, it might be better to step down therapy for those 
with better prognosis to decrease the long term sequelae and to improve their quality of 
life.  
Comparison of QOL of life of survivors who had posterior fossa syndrome in the post-
operative period, with those who did not have posterior fossa syndrome in the post-
operative period 
Since it is well known that posterior fossa syndrome(PFS)  often has prolonged effects on 
cognition, speech, balance, etc, QOL of survivors who had had posterior fossa syndrome 
were compared with that without posterior fossa syndrome. 3/11 with posterior fossa 
syndrome, were compared with 30 without PFS  Children with PFS scored less in all domains 
but  the numbers were too small to show a statistically significant difference  between the 
groups.  
Table No. 35: Comparison of QOL scores  of those who had posterior fossa syndrome 
vs those who did not have posterior fossa syndrome  
Domain QOL-
physical 
QOL-
emotional 
QOL-
social 
QOL-
school 
QOL-
psychosocial 
QOL-total 
PFS(n=3) 62.49+/- 
17.8 
65.00+/- 
12.9 
63.33+/- 
12.8 
60.00+/-
16.2 
62.77+/- 
11.9 
62.67+/- 
13.1 
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No  
PFS(n=30) 
67.74+/- 
20.4 
68.21+/- 
15.0 
72.50+/- 
2.9 
62.85+/- 
5.0 
67.73+/- 6.3 67.87+/- 
10.9 
P value 0.545 0.611 0.111 0.377 0.284 0.348 
 
Comparison of quality of life among those with gross total resection of tumour with 
those with subtotal resection of the tumour:  
The quality of life of those who had  gross total tumour resection was compared with those 
who had had subtotal tumour resection. Among the 33 patients who had quality of life 
assessment done, 15(45%) had undergone subtotal resection, whereas 18(55%) had 
undergone gross total resection. The quality of life characteristics of the group is depicted in 
Table No.36: Comparison of QOL scores among those who had subtotal resection and 
those with gross total resection.   
Domain Physical 
QOL 
Emotional 
QOL 
Social 
QOL 
School 
functioning 
QOL 
Psychosocial 
QOL 
Total 
QOL 
Subtotal 
resection(n=15) 
64.7 62.8 70.4 60.4 64.5 64.6 
Gross total 
resection(n=18) 
69.3 72.1 72.7 64.4 69.5 69.7 
P value 0.486 0.062 0.619 0.510 0.277 0.311 
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Levene’s test for equality of variances was applied to the above data, to look for any 
significant difference between the QOL scores among the two groups. There was no 
statistically significant difference obtained on the analysis.. 
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DISCUSSION 
In this study we looked at clinical profile, treatment and outcome of children diagnosed to 
have medulloblastoma in our centre from 2004 till 2014. We also looked at the tumour 
immunohistochemistry of selected cases and grouped them into molecular subgroups. We 
then looked at the clinical profile and outcome of the various molecular subgroups as well. 
Assessment of quality of life of survivors was another arm of this study. There were 149 
cases of medulloblastoma; 109 were in children less than 16 years of age.  Only 68% 
(76/109) reported to the Paediatric Haematology -Oncology unit.   
Clinical profile  
The mean age at presentation of children in our study was 8.49 with a median age of 8 
years. There were 7 children who were <3years at diagnosis. The male: female ratio was 
1.8:1.  This profile is similar to the series published by Packer et al (1)  Most children 
presented with features of raised intracranial pressure.  Cerebellar symptoms were less 
common, probably because 84% of tumours were in the midline. The mean duration of 
symptoms prior to presentation was 2.7 months, with a range from 1 week to 12 months. 
This  again was similar to data from  Packer et al   where the mean duration of symptoms 
was  3 months.(1)  
30% of our study population needed emergency CSF diversion procedures. Gopalakrishnan 
et al also found that about one third of their patients needed  CSF diversion surgeries. (49) 
All children underwent surgical excision of the tumour. Based on resectability and residual 
tumour, children were divided into those who had gross total resection vs subtotal 
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resection, where the residual tumour volume was >1.5cm2 vs <1.5cm2. In our group 48% 
(37/76) underwent gross total resection. In a series published by Gajjar et al, 50% of children 
with midline tumours had gross total resection.(86) Post operative complications in our 
study group showed meningitis in 24%, posterior fossa syndrome in 14% and CSF leak in 
12%. Compared to published literature, Wells et al and Muzumdar et al had shown posterior 
fossa syndrome in upto 25 % of the patients after surgical resection of tumours. (23)(47) 
Risk stratification  
The various histological types of medulloblastoma as per WHO 2007 classification are  
classical, desmoplastic, medulloblastoma with extensive nodularity, anaplastic variant and 
large cell variant. (14). All five histological types were seen in our series too, with classical 
being the commonest followed by desmoplastic.  
For all cases of medulloblastoma, after surgical excision of tumour further investigations are 
performed to ascertain risk groups. These include volume of residual tumour and localised 
versus metastatic disease. Residual tumour volume should be assessed using MRI scan done 
within 72 hours of surgery as per guidelines, but in our centre, due to various reasons, 
contrast CT scan is performed and there is no recommendation for ideal time for the scan as 
contrast enhancement will be able to differentiate between blood and residual tumour.   
The interval between surgery and post-operative imaging varied widely in the study group, 
from 1 day to 32 days after surgery, with a mean duration of 7.05 days +/-5.53.  Post-
operative imaging was done in 14/76(18%) before 72 hours and in the remaining 
62/76(82%) it was done after 72 hours. 28/76 had no residual tumour, 18 had <1.5cm2, 9 
had 1.5-3cm2 and in 21 the residual tumour measured more than 3cm2.  So as per risk 
stratification criteria  based on residual disease 30/76(40%) had high risk disease.  
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For evaluation for metastatic disease MRI spine and CSF cytology were done. Both tests are 
recommended as one or the other alone reduces the pickup of metastatic disease as 
reported by Fouladi et al (40).  58/76 (76%) had MRI spine and 46/76 (61%) had CSF cytology 
and 39/76(51%) had both CSF and MRI spine done. All children had one or the other test 
done. 23/58 had drop metastases and 9/46 were positive for malignant cells in CSF.  Based 
on cytology and/or MRI spine screening 27/76 (36%) had metastatic disease in this series.     
  
Lafay Cousin et al reported  the rate of metastatic disease to be 28-55% in children <3 years, 
compared to 15-40 % among older children(36). In our study, however, we had 28 % 
disseminated disease among those younger than 3 years, and 36% disseminated disease in 
those older than 3 years at the time of diagnosis.  There was no statistically significant 
difference between the two groups, (p value =0.24) probably because of the smaller 
numbers in <3 years age group.   
 
Metastatic disease did seem to be more frequent in those who had had a longer duration of 
disease(44%) , compared to those who had had symptoms for less than 3 months’ duration 
(32%), however this did not show statistical significance (p= 0.112) 
When we compared various histological types of medulloblastoma with age, residual 
tumour and dissemination, we did not find any significant correlation.  
Overall, based on various risk stratification parameters, 10% were <3 years of age at 
diagnosis, 40% had residual tumour >1.5cm2 and 36% had metastatic disease.  57% (43/76) 
of our patients had high risk disease.  
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Treatment and Outcome 
The various treatment modalities for medulloblastoma include surgical excision, 
radiotherapy and chemotherapy. All our patients underwent surgical excision and 60 
received chemotherapy and RT (if age appropriate). 21/76(28%) abandoned treatment.  
Radiotherapy was well tolerated. However, chemotherapy was found to be quite toxic. Only 
36/60 received 8 cycles of PCV chemotherapy. Significant side effects such as ototoxicity, 
cytopenia, neurotoxicity and nephrotoxicity were responsible for treatment modifications. 
Similar toxicity profile is reported in literature. (58-63)   
 
50% of our patients completed treatment and 25% died of disease or other complications. 
34 children were alive and were on follow up. Of these 2 were on treatment for relapse. 
32/76 (42%) were in CR at the time of analysis. Data of 19 children who died showed that 
14/19 (74%) had high risk disease. The mortality rate among those with standard risk 
disease was 15% (5/33) and those with high risk disease it was 33 %( 14/43).    
Outcome was compared with various risk factors;  Sarkar etal , Caputy et al, verma et al 
described that classic histology, desmoplastic and MBEN had a better outcome compared to 
anaplastic type. (87, 19, 5)  We also found a similar trend (p= 0.054) towards significance.  
Other risk factors on outcome were not significant.  
 Molecular subgroups 
Boston Consensus 2010 classified medulloblastoma based on their immunohistochemical 
properties into 4 subgroups: WNT(wingless), SHH(sonic hedgehog), Group 3 and Group 4.  
Each of these subtypes have distinct demographics, clinical presentation, associated genetic 
abnormalities as well as final outcome, as detailed by Taylor et al in their landmark paper in 
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Acta Neuropathologica.(6) With the help of immunohistochemical markers, the tumour can 
be divided into these 4 subgroups, which will not only help in prognostication, but also in 
targeted therapies, such as SHH inhibitors for sonic hedgehog group. (23) 
 
We did molecular subgrouping of 43 patients using beta catenin and histology. 26/43 (60%)  
belonged to the WNT subgroup, 30% in SHH subgroup and 10% in non WNT/non SHH 
group. Our observation is quite contrary to that published by Ellison et al where only 10% 
was WNT, 30% SHH and   60%  belong to group 3 /4  ie non WNT /non SHH. (24)  It is 
difficult to comment on this difference as there is no published literature from India.   
 
Comparison of molecular types  with histology showed that while WNT subtype mainly 
consisted of classic subtype, with large cell anaplastic variant forming a small part as well, 
SHH was formed of desmoplastic and MBEN variants, and non SHH/ non WNT were 
composed of classic as well as LCA histology. This is in accordance with the accepted 
characteristics of these subgroups as shown by Ellison et al. (26) 
 
On comparing the molecular subgroups with the risk stratification, assuming WNT to have 
good prognosis and non WNT subgroup to have poor prognosis, the analyses was shown to 
approach significance (p=0.056) 
 
For analysis of outcome we compared WNT with non-WNT and found a significant 
difference in outcome (table no 30) p=0.016  The better prognosis associated with the WNT 
subgroup is very well known, as shown by Ellison et al. (32) 
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We compared molecular subtype with location of tumour as per radiological image.  
Perreault et al had shown that group 3  and group 4 tumours are mostly midline, whereas 
WNT tumours are usually cerebellopontine in location and SHH tumours are mostly lateral 
(cerebellar) in location. (38) However, in our study, 81% of all tumours were midline in 
location, with the remaining 19% being cerebellar and cerebellopontine. There was no 
correlation between the tumour location and molecular subgroups in our study.  
 Late effects      
The delayed complications of therapy were analysed in 48 children. Cisplatin induced 
hearing impairment was the most common delayed complication in our group.  Endocrine 
related complications included hypothyroidism in 19, growth hormone deficiency in 4, 
hypocortisolism and premature ovarian failure in two. Cisplatin induced tubulopathy 
presenting as hypomagnesemia and hyponatremia were rare, but interesting late effects in 
our group. Permanent hair loss, which was seen in 22 patients, was reported by many 
patients as well as parents, especially when the patients were in the adolescent age group, 
to be a source of embarrassment and self- consciousness in the children. 14 of these 
patients had sought treatment for the same, however there was no improvement noticed 
with the same. These late effects were also seen in other published series also (54-57, 58-
62, 64-66)                      
Quality of life of survivors 
Assessment of quality of life of survivors was done using Peds QL, a validated quality of life 
assessment tool, as described in the methodology. According to the mapi-organisation, a 
perfectly normal child would have a QOL score of 100.  
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The mean quality of life scores in all domains were less than 75 for all survivors, indicating 
that quality of life in all domains are definitely affected to some extent in all survivors. 
Kulkarni et al had studied the quality of life of 62 patients who had completed treatment for 
posterior fossa brain tumours, at a mean interval of 5.2 years after completion of treatment, 
using the same tool, PedsQL(84). In this study, the median score was 78.4(64.1-92.4). Our 
results are similar to that of Kulkarni et al. An interesting observation published by the same 
author states that QOL was similar in general population when compared with those who 
had had treatment for posterior fossa tumours. An explanation for this is probably because 
perceived quality of life by both survivors and care takers are much higher than functional 
ability of the child. This was observed by Maddrey et al (81)  
Quality of life assessment of various risk groups and molecular subtypes did not any 
significant difference. Those with recurrence of tumour showed some difference, but the 
numbers were too small to draw any conclusion.   
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SUMMARY: 
 
•    76 children with medulloblastoma, seen in pediatric hematology-oncology  unit from 
2004-2014 were included in this study, to compare clinical profile and outcome with 
molecular subgroups. 
 
      The age at presentation ranged from 1 year to 15 years, with a mean of 8.49. The male: 
female ratio was 1.8:1. The mean age at presentation was 8.49 years.  Headache, vomiting 
and ataxia were the common presenting symptoms. 78% of these children presented to 
hospital within 3 months of onset of symptoms.  
 
       Various treatment modalities of medulloblastoma include emergency shunt surgery, 
followed by excision of tumour, radiotherapy and chemotherapy. All children underwent 
surgical excision; 29% required emergency CSF diversion surgery.  60 children received 
chemo-radiotherapy.  
 
         Children with medulloblastoma were risk stratified based on age less than or more than 
3 years at diagnosis, residual tumour volume of 1.5cm2 or more and localized versuss 
metastatic disease.  7/76 children were less than 3 years of age at diagnosis, 30/76 had a 
residual tumour volume of >1.5cm2 and 27/76 had metastatic disease. Overall, 43/76 (57%) 
had high risk disease. 
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•     Molecular subgrouping of 43 children with medulloblastoma was done using beta 
catenin and histology. 26/43 (60%) belonged to the WNT subgroup, 30% in SHH subgroup 
and 10% in non WNT/non SHH group.  These results were different from other published 
data, where WNT group was the least common.   
•        60/76 received all three modalities of treatment. Rate of abandonment of treatment 
in this group was 21%.  34 children completed treatment and were assessed during the 
study. 19 children died, all except one due to disease.  
 18/33 (55%) children with standard risk disease were alive and in CR compared to 
16/43(38%) with high risk disease. Mortality was found to be higher in those with high risk 
disease, anaplastic histology and non-WNT type of medulloblastoma, but these observations 
were not statistically significant.  
• Late effects of treatment assessment showed high incidence of hearing impairment, 
 hypothyroidism, alopecia and tubulopathy. Many children reported poor scholastic 
 performance.  
 Quality of life assessment done  usingPeds QL, a validated quality of life assessment 
tool, in 33 children, where physical, emotional, scholastic, social and psycho-social domains 
were tested. It is proposed that a normal child will have a score close to 100. The mean total 
QOL score in this population was 67.4.   QOL scoring was compared between various 
parameters such as  extentof surgery, posterior fossa syndrome and those with recurrence 
of tumour. There was significant difference in QOL scores between those in CR compared to 
those with disease recurrence.   
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LIMITATIONS 
1. Since most of the data was collected retrospectively from medical records, some 
relevant data  was missing.  
2. For molecular subgrouping of medulloblastoma, we planned to use 2 
immunohistochemical markers, however only beta-catenin was standardized  for use during 
the study period. Use of both immunohistochemistry markers would have provided more 
accurate subgrouping. 
3. Perceived quality of life by the survivors and their parents seemed to be higher than 
their actual quality of life. This might represent a bias in perception on the part of the 
patients and their families . 
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2. Annexure number 2: Patient information sheet: 
PATIENT INFORMATION SHEET 
 
This information sheet will explain to you the details regarding the present study. Kindly go 
through this carefully. You are free to clear your doubts before consenting to participate in 
this study. 
TITLE OF RESEARCH: 
Pediatric Medulloblastoma: comparing clinical profile and outcome with  molecular sub groups 
PERSON CARRYING OUT RESEARCH:  Dr. Leenu Lizbeth Joseph 
I’m Dr. Leenu Joseph, a PG  registrar working in the department of  paediatrics , CMC Vellore. I am 
doing a study on quality of life in children with medulloblastoma who were treated in the 
PaediatricHemato-oncology OPD between 2004 and 2014. Details of the study are given below.I 
would like you to be part of this study, but the choice is yours; you can decide not to take part in 
this study . I am happy to clarify your doubts, if there are any.  
This study will be done among children who have been treated for medulloblastoma in this unit. 
You will be asked to fill a questionnaire regarding how you/ your child is able to carry out activities 
of daily living as mentioned in the questionnaire. You can clarify all your doubts regarding the 
questionnaire with me.  
Medulloblastoma is a type of brain tumor. As you are aware your child/you was/ were treated for 
this in the past. We will be using information from their clinical records such as details of presenting 
symptoms, investigations, treatment and complications. We would like to know how you/ your child 
is coping with daily activities of living. For this, we would like you to answer a few questions. There 
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are 23 questions in this questionnaire. If you cannot understand what the question means, I can 
clarify your doubts for you. There are no right or wrong answers. If you feel unable to answer a 
certain question even after clarification, it is acceptable not to answer the same. Treatment for your 
child will not be altered in any way based on your answers. 
 
CONFIDENTIALITY: 
Your child’s name will not be mentioned anywhere neither in the data sheet nor in the final 
published study. Your data will bear a study number and the number will be used till analysis. The 
master sheet will have your study  
number. 
SHARING OF THE RESULT: 
 The results of research are property of Christian medical college and I'm entitled to publish it in a 
journal or present in a conference. 
This proposal has been reviewed and approved by [IRB, Christian Medical College], which is a 
committee whose task it is to make sure that research participants are protected from harm.  If you 
wish to find  more about the IRB,  
Contact  
Research Office, 
Second floor, Carman block,  
Christian Medical College,  
Bagayam, Vellore 632002.  
Email: research@cmcvellore.ac.in, Telephone: 04162284294.  
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It has also been reviewed by the Ethics Review Committee CMC Vellore, which is supporting the 
study. In case of doubts or questions, please contact Dr.Leenu Lizbeth Joseph.Department of 
Paediatrics, Christian Medical College and Hospital, Vellore. Ph.No.9486909752 
 
3. Annexure number 3: Certificate of Consent/ Assent 
 I have read the foregoing information/ it has been read to me. I have had the opportunity 
to ask questions about it and any questions that I have asked have been answered to my 
satisfaction.  I consent voluntarily to participate as a participant in this research. 
 
Print Name of Participant__________________   
Signature of Participant ___________________             
Date ___________________________                             
              Day/month/year                                                                                      
    
 
If illiterate Thumb impression (R / L) 
 
I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has 
given consent freely.  
 
Print name of witness_____________________             and     Thumb print of participant 
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Signature of witness ______________________ 
Date ________________________ 
                Day/month/year 
 
Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to the best 
of my ability made sure that the participant understands that the following will be done: 
 
1. Filling a questionnaire regarding the current functional status of my child accurately to the 
best of my ability 
2. Participation is voluntary and there will be no extra costs/ any changes to my child’s 
treatment/ any benefits to my child 
 
I confirm that the participant was given an opportunity to ask questions about the study, 
and all the questions asked by the participant have been answered correctly and to the best 
of my ability. I confirm that the individual has not been coerced into giving consent, and the 
consent has been given freely and voluntarily.  
A copy of this ICF has been provided to the participant. 
 
Print Name of Researcher/person taking the consent-Dr. Leenu Lizbeth Joseph  
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________  
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Annexure number 4: Permission from mapi organisation for using PedsQL 
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1. Annexure number 5: PedsQL 
 
 
